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s u mmary
1. The literature concerning measurement and stability of the 
oestrogen nuclear receptor has been reviewed in relation to the use 
of receptor assays for management of breast cancer.
2. The influence of temperature and ionic strength on the stability
of the human nuclear oestrogen receptor complex was studied in
relation to the major methods used to assay for nuclear receptor.
3The exchange rate of ( H) - oestradiol from the nuclear receptor 
was measured as a decrease in specifically bound labelled oestradiol 
during an incubation with an excess of unlabelled oestradiol.
3. When the nuclear oestrogen receptor complex was bound to intact 
nuclei, the rate of exchange increased with temperature but a
significant exchange could be measured over 24 hours at 4°c. The
use of protease inhibitors together with re-labelling of nuclear 
receptor after incubation confirmed that the observations represented 
exchange of hormone rather than degradation of the hormone receptor 
complex.
3
4. Measurement of the on-rate of ( H) - oestradiol to the oestrogen 
nuclear receptor, prefilled with unlabelled oestradiol, also demonstrated 
that there was a significant rate of exchange of hormone at 4^c.
5. The exchange rate from salt extracted, hydroxylappatite 
precipitated receptor also increased with temperature. However, this 
extracted complex was more stable and no exchange could be detected 
at 4°c.
- X X  -
6. Only 50% of total detectable human nuclear oestrogen receptor 
was solubilised by the standard method of salt extraction in 0.6m  KCl. 
As the salt concentration was raised (0 - 0.6M KCl) an increase
in stripping of oestradiol from the hormone receptor
complex was observed. This would create a false impression of the
proportion of "empty nuclear receptor".
7. These results were compared with other reports of the stability 
of the hormone receptor complex. The consequences of these results 
were discussed in relation to current nuclear oestrogen receptor assays 
and their use in stratifying therapy for patients with breast cancer.
8. The literature concerning current iu vitro models of human 
breast cancer has been reviewed and the merits of these models have 
been compared.
9. A method has been developed for the routine primary culture
of cells from breast cancer biopsies. This method involved digestion 
with collagenase followed by growth on a feeder layer. Approximately 
85% of biopsies gave rise to viable primary cultures.
10. Growth of these cells was in the form of ring colonies which could 
be maintained in culture for up to 3 months. Cells were characterised 
as epithelial by electron microscopy and immunofluorescence and tests 
were carried out to demonstrate the retention of malignant potential.
11. The effect of hormones and growth factors on the growth of cells 
in the ring colonies has been investigated. In particular cortisol
- X  -
and oestradiol were found to act synergistically to stimulate growth. 
Cholera toxin, prolactin and cortisol were found to stimulate growth 
or plating efficiency to a lesser extent. Epidermal growth factor 
did not stimulate growth of breast epithelial cells. The effect 
of these hormones was compared with published reports of other 
in vitro systems.
12. Differences between primary tumours (such as oestrogen receptor 
status or growth rate) were reflected by the growth and the response 
to hormonal stimulation of the ring colonies,
13. A method was developed, using autoradiography, to measure the
3
effect of hormones and growth factors on ( H) thymidine incorporation in 
a small number of cultured breast epithelial cells. The possible 
applications of this system have been discussed.
PART I
The stability of the human nuclear oestrogen receptor
1. INTRODUCTION
1.1 CONTROL MECHANISMS
Both the functions of the body and its response to environmental 
fluctuations are regulated by two major control systems: the nervous
system and the hormonal or endocrine system. There is interaction 
between neural and endocrine control at several levels but, in general, 
the nervous system controls the rapid activities of the body, such as 
muscular contractions, by the transmission of electrical impulses along 
a network of nerve fibres. On the other hand, the endocrine system 
is concerned principally with the different metabolic functions of 
the body, including aspects of cellular metabolism, growth and 
differentiation. The effects of a hormone can take place in seconds 
or over a period of many years.
A hormone is a chemical substance that is secreted into the body fluids 
by one cell, or a group of cells, and then exerts a physiological 
control effect on other cells of the body, classically at a distant 
site- In general, a hormone is secreted by a specific endocrine gland 
and is transported in the blood to cause physiological actions at 
distant, so called target tissues. Hormones can affect either one 
or more target tissues and a given tissue can be responsive to more 
than one hormone. The classical concept of a distant target tissue 
may have to be modified to include prostaglandins, interferon and some 
of the hormones such as secretin released in the gastrointestinal 
tract and growth hormone release inhibiting factor produced in the 
D cells of the pancreas, which are able to exert their effects on cells
—  3 —
in the same tissue. The specificity of a hormone is determined by 
the presence of a chemical receptor (the entity with which the hormone 
interacts in order to initiate a response) on or in the target cell.
Chemically, hormones can be divided into three classes -
a) the amino acid derivatives, e.g. the catecholamine, adrenalin®
b) the peptide hormones, e.g. insulin
c) the steroid hormones, e.g. testosterone
Studies on the molecular mechanism of hormones led to the division of 
hormones into two groups depending on whether the hormones acted at 
the cell surface or entered the cell. This separation has recently 
become blurred (Kolata, 1978; Kahn ^  1981; Posner ejk a^, 1981)
because of evidence of internalization of plasma membrane hormone/receptor 
complexes.
1.2 STRUCTURE OF STEROID HORMONES
All steroids are derived from cholesterol which is a constituent of
virtually every animal tissue and occurs partly as a free alcohol and
partly esterified with higher fatty acids. The cyclohexane rings 
adopt the most stable *chair* conformation resulting in the three 
dimensional structure of steroid hormones (figure 1.1). A set of 
rules for the systematic nomenclature of all steroids has been defined 
by the International Union of Pure and Applied Chemistry (lUPAC - lUB,
19693 1971). Virtually all steroids can be defined with reference 
to choiestane by removal of all or part of the carbon side chain 
(figure 1.2).
Figure 1.1 - The Structure of Choiestane
A. Two-dimensional representation of the structure 
of Cholestane.
B, Representation of the three-dimensional structure 
of Cholestane.
- -
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Figure 1.2 - Structural Relationship between Cholestane and Cholane,
Pregnane, Androstane and Oestrane.
Examples of the biologically important steroids related 
to each parent hydrocarbon are also shown.
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1.3 SYNTHESIS OF QESTROGENS
The ovaries are the main source of oestrogens in premenopausal women. 
During the early stages of the menstrual cycle oestrogens are synthesised 
in the graafian follicle by aroraatization, in the granulosa- cells, of 
androgens produced by theca cells. After ovulation oestrogens are 
produced in the resulting corpus luteura. Oestrogens both stimulate 
the growth and development of the female reproductive organs and induce 
the secondary sex characteristics. The growth responses include 
proliferation of the epithelium of the fallopian tubes, endometrium, 
cervix and vagina. Oestrogens in concert with pituitary hormones, 
progestins and glucocorticoids, stimulate mammary growth though the 
precise balance of hormones required for mammary development varies 
among species.
In the ovaries, cholesterol is converted to oestrogen, via the androgens. 
Oestrogens are also produced from other sources, e.g. the testes are 
able to produce oestrogens and the adrenals can synthesise small 
quantities of oestrone. Other recent work has revealed that peripheral 
tissues contain an aromatase, associated particularly with adipose 
tissue, which has the ability to utilize plasma -4- androstenedione 
and testosterone to synthesise oestrogen both in men and women. In 
postmenopausal women most of the circulating oestrogens come from 
plasma-4-androstenedione (Jensen, 1979).
In 1960 Jensen and Jacobson prepared tritiated oestradiol of high 
radiospecific activity and demonstrated the uterus and the vagina as 
target tissues. Later the hypothalamus,anterior pituitary
(Eisenfeld & Axelrod, 1966) and the breast (Sander, 1968) were also 
shown, through retention of steroid, to be target tissues.
The most biologically active of the natural oestrogens is oestradiol - 17^, 
but both oestrone and oestriol can be important under certain conditions. 
Oestrone activity was thought to result from its conversion to 
oestradiol - 17^ (Williams - Ashman & Reddi, 1971). It was later 
shown to be effective at higher concentrations than were required for 
oestradiol U f i (Ruh ejt 1973) but acted as an antagonist when both
were injected simultaneously. This was due to the lower affinity of 
the oestrogen receptor for oestrone (Lbvgren ^  al^ , 1978) so that it 
did not maintain receptor in the nucleus for an adequate period (Lan 
& Katzenellenbogen, 1976). When a pellet of oestrone was implanted 
to maintain the plasma concentration, and so re-cycle receptor, it was 
found to be a potent oestrogen. A similar argument explains the 
biological activity of oestriol (Clark & Peck, 1979).
1.4 MECHANISM OF ACTION OF STEROID HORMONES
Steroid hormones are normally found in the plasma at levels less than 
-810 M although the actual levels vary from species to species. They 
are transported bound to serum proteins to (1) protect them from liver 
metabolism (2) overcome their relative insolubility and (3) provide an 
immediate store of steroid. Some steroid hormones bind largely to 
one plasma protein, i.e. cortisol binds principally to cortisol binding 
globulin (CBG) while others bind to several with relatively low affinity, 
e.g. aldosterone. At normal blood levels (in humans '-^ 10'"^ M^) most 
oestrogen is bound to steroid binding globulin (SBC), with weak binding
Figure 1.3 - Mechanism of Action of Steroid Hormones
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to every plasma fraction (Sandberg ej^  al, 1957), At higher 
concentrations, such as during pregnancy, binding to albumin and 
e^^-globulin predominates (King & Mainwairing, 1974).
Despite the proposal, on several occasions, of a transport mechanism 
for cellular uptake of oestrogen (Milgrom et al,1973) or corticosteroids 
(Harrison ^  al, 1974; Svyemisto & Terayama, 1975), it is now generally 
accepted that entry into the cell is by passive diffusion (Gorski &
Gannon, 1976; Giorgi & Stein, 1981). Shortly after an injection of 
radioactively labelled steroid hormone, it can be detected in all 
tissues (Jensen & Jacobson, 1960; 1962). The possession of a 
relatively small number (10 - 20,000/cell) of highly specific receptor 
molecules is responsible for the retention and, possibly, concentration 
of hormone within a cell and the presence of such receptors defines 
a target tissue (Folca,/\ 1961 ; Clark & Gorski, 1969; Clark & Peck, 1979; 
Leake, 1981a). The unfilled receptor molecule is thought to be free 
in the cytosol or loosely associated with the membrane of the cell 
and the endoplasmic reticulum (Wittliff, 1975; Pietras & Szego, 1979;
Muller et 1979),
In 1968 the two groups of Jensen and Gorski separately proposed a 
general two step mechanism for oestrogen action (figure 1.3) (Gorski 
et al, 1968; Jensen al^ , 1968), The research that led to these 
theories, and much of the subsequent research on oestrogen action, 
involved studying its effects on the immature rat uterus (Jensen al, 
1974) and, later, on chick oviduct (0*Malley et al, 1976), The two 
step mechanism has also been demonstrated for progesterone (Schwartz e^ al,
1976), androgens (Mainwairing & Peterken, 1971), glucocorticoids
- 10 -
(Rosseau et 1973), raineralocorticoids (Edelman e_t 1968), and
vitamin D (Brumbaugh & Haussier, 1974).
After binding to the receptor in the cytosol, the hormone - receptor
complex is thought to be activated by the addition of a polypeptide 
(Notides & Nielson, 1974; Leake, 1976; Tharapan & Clark, 1981), The
site of activation is unknown but the process is reported to be heat
dependent (Jensen elb ai, 1974) and to permit translocation of the 
hormone receptor complex across the nuclear membrane into the nucleus,
A positive role for the nucleus has, however, been discounted (Linkie 
& Siiteri, 1978), Once in the nucleus the complex binds to specific 
acceptor sites on the chromatin (Spelsberg et ai, 1975; De Boer e;t al,
1977) where it regulates gene expression. The acceptor site (see 
section 1.9,2) is thought to be defined by some combination of non 
histone protein and DNA (Spelsberg, 1974; Clark & Peck, 1979; Leake, 
1981a).
The first effects occur rapidly after hormone administration and include 
an increase in hnRNA and mRNA synthesis (Spelsberg, 1976; Aziz & 
Knowler, 1978; 1980), The hormone receptor complex is released from 
the chromatin after retention for a specific time (Clark & Peck, 1976;
1979), Horwitz & McGuire (1978a;b ; 1980) have recently suggested 
that processing of the nuclear receptor complex must occur before 
induction of protein synthesis.
In general the steroid hormone is released from the cell unmetabolised 
(Puca & Bresciani, 1968). Exceptions are the androgens, which are 
metabolised to their active form, dihydro, testosterone, in the target
- 11 -
cell prior to action, and some breast cancers which are able to 
metabolise steroids (King et^  al^ , 1965; Castagnettes et al^ , 1980;
Miller ejt al, 1981). The level of receptor in the cytoplasm is 
replenished by a combination of de novo synthesis and recycling (Clark 
& Peck, 1979). After release from the cell, steroid hormones are 
removed from.the bloodstream by the liver and then excreted, primarily 
as conjugates of glucuronic acid and sulphuric acid.
1.5 KINETICS OF OESTRADIOL - INDUCED RESPONSES IN TARGET TISSUES
In the immature rat uterus the effects of oestrogen are characterized 
by hypertrophy followed by hyperplasia. The earliest detectable 
response is an increase, starting after 15 mintues, in RNA polymerase II 
activity. This peaks at 30 minutes and returns to control values 
within 2 hours (Classer et aj, 1972; Borthwick & Smellie, 1975).
By 30 minutes there is a detectable stimulation in the synthesis of 
hnRNA (Knowler & Smellie, 1971 ; 1973), with an increased content of 
sequences complimentary to mRNA (Aziz & Knowler, 1978; 1980). This 
is followed by the appearance of hnRNP particles (Knowler, 1976) and 
the aggregation of existing ribosomes into polysomes containing newly 
made mRNA (Merryweather & Knowler, 1980),
One hour after oestradiol administration synthesis of rRNA is stimulated 
and this peaks at 2 - 4 hours (Knowler & Smellie, 1973) although 
accumulation of new rRNA into ribosomes does not reach a peak until 
12 hours. Inhibitor studies suggest that the stimulation of rRNA is 
dependent on prior stimulation of hnRNA synthesis and protein synthesis 
(Gorski, 1964; Borthwick & Smellie, 1975). A similar result was
- 12 -
obtained for glucocorticoid stimulation (Chen & Feigelson, 1979) 
suggesting that early protein synthesis is a prerequisite for many 
of the later steroid hormone-induced genetically-mediated responses.
Other early effects that have been reported are increased fluid 
retention, increase in nucleotide precursor uptake and changes in 
cyclic nucleotide levels (cAMP ^  cGMpt ) (Kuehl ^  al, 1974; Ni col 
et al, 1974). The increase in cGMP is inhibited by actinomycin D 
(Nicol & Goldberg, 1976; Flandroy & Galand, 1979) suggesting the increase 
occurs subsequent to a transcriptional event. The increase in fluid 
retention is, however, thought to occur independently of transcription 
as a result of eosinophil migration to the uterus (Tchernitichin,
1979; 1982). Other oestrogen induced but non-receptor mediated 
responses, include an increase in glycogen, and induction of several 
glycogenolytic enzymes and a cervicovaginal antigen (Tchernitichin,
^  a]^ , 1975; 1977). Jensen & De Sombre (1972) reported an early rise 
in mRNA, phospholipid and glycogen synthesis followed (6 - 12 h) 
by a rise in total protein, RNA. and DNA, The first specific protein 
to be induced is ip which has been recently characterized as 'brain type* 
creatine kinase (Kaye, 1979; 1982).
Late responses to oestrogen include a sustained high RNA polymerase I 
activity, a second rise in polymerase II (Glasser et 1972; Borthwick
& Smellie, 1975) and a sustained increase in glucose metabolism (Gorski 
& Raker, 1973), There is a general growth and division of cells, and 
the receptor must remain in the nucleus for 6 - 1 2  hours to elicit these 
'late* responses (Clark & Peck, 1976; 1979).
Since RNA polymerase activities were measured in isolated nuclei, it is
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possible that they reflect changes in template activity rather than 
enzyme activities. When Borthwick & Smellie (1975) extracted and 
fracti oned uterine RNA. polymerase I and II, no oestrogen induced 
effects were observed. Tsai e^ a]^ , (1975) studying chick
oviduct found an increase in initiation sites available to kind RNA 
polymerase after oestrogen stimulation. A similar level of increase 
in initiation sites was found for oestrogen in rat uterus (Markaverich 
et al, 1978), for progesterone in chick oviduct (O'Malley e^ aG, 1976) 
and for androgen in rat prostrate (Thomas e^ 1977). However, there
have been doubts expressed (Parker & Roeder, 1977) over the validity 
of the rifarapicin challenge assay used to quantify initiation sites 
(Tsai, a3^ , 1975) since it uses a bacterial RNA polymerase though the 
study of Thomas _et_ (1977) used an animal polymerase. Pa Imiter & Lee 
(1980) have concluded that the increase in RNA synthesis detected in 
chick oviduct is an artefact produced by transcription of contaminating 
ovalbumin mRNA. Nevertheless, most authors are in agreement that 
hormone treatment does increase the number of initiation sites. In 
the chick oviduct the secretion of egg white proteins ovalbumin and 
conalbumin are under the control of oestrogen and progesterone. 
Hybridisation techniques with cDNA were used to show an increase in 
ovalbumin mRNA production from zero to 48,000 molecules per cell which, 
after withdrawal of oestrogen treatment, decreased to zero (Harris ^  al, 
1975; 1976). The differential control of oviduct genes by steroid 
hormones was studied by Pa Imiter ^t a]L (1976; 1981) who found that 
conalbumin gene transcription was linearly related to receptor levels 
while ovalbumin gene transcription was related to receptor levels in a 
manner indicative of co-operative interactions among receptors during 
induction. This result, in combination with the effect of simultaneous
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progesterone administration on the kinetics of synthesis of the two 
proteins, has led to the conclusion that a single receptor binding site 
is involved in conalbumin gene regulation and multiple sites are 
involved in ovalbumin gene regulation (Compere et al, 1981; PaImiter 
et al, 1981). This led PaImiter et ad (1981) to propose a model based 
on multiple regulatory sites and intermediary proteins to explain both 
the synthesis of ovalbumin and conalbumin and the apparent interaction 
between the androgen, progesterone and oestrogen nuclear receptors in 
controlling their synthesis,
1.6 OESTROGEN RECEPTOR
The oestrogen receptor was first characterized in immature rat uterus 
by Toft & Gorski (1966) as a protein of molecular weight 80,000. More 
recently the oestrogen receptor from calf uterus has been purified to 
homogeneity by affinity chromatography (Sica & Bresciani, 1979). The 
dissociated form has a molecular weight of 70,000 by SDS gel electrophoresis 
comparing with 76,200 for the rat uterus receptor (Jensen & De Sombre,
1972) and 50,000 for the receptor from human breast cancer cells (Greene 
et al, 1980). The similarities between different species are 
demonstrated in the cross reaction of monoclonal antibodies across a 
wide variety of species (Greene et al, 1980; Greene & Jensen, 1982),
There is still uncertainty regarding the molecular weight of, and number 
of subunits in, the native functional form of the protein (Sica &
Bresciani, 1979).
The oestrogen receptor protein is heat labile (McGuire & De La Garza,1973) 
and has iso-electric points at pH 5.9 and 6.7 corresponding to the two
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molecular forms (Gustafsson et al, 1978), It has a sulphydryl group 
which is important both to maintain the conformation and for the 
steroid/receptor interaction (Jensen et ad, 1967; King et 1979b),
The receptor is destroyed by repeated freezing and thawing (King ^  al, 
1979b; Sica & Bresciani, 1979). Both the cytoplasmic and nuclear forms 
of the receptor demonstrate a marked tendency to aggregate (Stancel 
et al, 1973; Schneider & Gschwendt, 1980) and this probably accounts 
for many of the problems encountered in trying to determine molecular 
weights. The concentration of receptors present in normal tissue 
depends on circulating levels of oestrogen, progesterone and prolactin 
(Sarff & Gorski, 1971; Asselin e_L 1977), This is demonstrated
by the cyclic variation of uterine receptors during the ovarian cycle 
in both rats and humans (Feherty e^ ad, 1970; Follow et a_l, 1975;
Soutter ^  1979).
1.7 CYTOPLASMIC BINDING
There are two types of cytoplasmic binding found in oestrogen target 
tissues. The high affinity site (type I) has a dissociation constant
(Kd) of 10 ^^M in human tissue (McGuire & Julian, 1971) and is the 
classical oestrogen receptor which undergoes translocation to the 
nucleus and mediates cellular activity (Feherty e^ 1971; King,
1975; Clark ej^  1978). Type I binding sites are thought to be
able to concentrate oestrogen within the target cell (Clark & Peck,
1979; Leake, 1981b).
The lower affinity binding sites (type II) have a dissociation constant 
(Kd) in humans of 3 x 10”^M, do not undergo translocation and have an
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ill-defined cellular function (Clark e]^  al, 1978; Eriksson et àl, 1978). 
Type II binding sites seem to be a general phenomenon. They are 
found in rat uterus (Clark _et 1978), chick oviduct (Smith ejt 1979)
and human breast tumours (Panko e]^  1981) for oestrogen, for
glucocorticoids (Barlow e;t al, 1979; Do et al^ , 1979) and aldosterone 
(parman et al, 1978). The situation has been further confused by the 
report of a third oestrogen binding site in chick oviduct (Smith &
Taylor, 1981) which can translocate, but which induces only some of 
the oestrogenic responses. This may be related to the report of 
Fishman & Fishman (1979) that the antioestrogen, tamoxifen, only binds 
to a proportion of soluble oestrogen receptors in human target cells.
Pietras and Szego (1977 ; 1979) have reported that the major portion 
of the cytoplasmic receptor is found in association with the plasma 
membrane, with lesser amounts in the lysosomal and mitochondrial 
fractions and with very little actually in the supernatant. However 
Muller et al (1979) claim that the receptor detected represents only a 
small portion contaminating the plasma membrane since mixing cytoplasmic 
receptor and rat diaphragm membrane demonstrates that the association 
is not tissue specific. But both Pietras and Szego (1979) and Parikh 
et al (1980) strongly dispute these claims.
Estimates of the size of the cytoplasmic form of the classical oestrogen 
receptor have varied from 7-lOS (Toft & Gorski, 1966; McGuire & Julian, 
1971; Wittlif & Savlov, 1978). In low ionic strength buffers it is 
now generally accepted to be, and is referred to as, 8S (Kute al, 
1978; Hawkins et aG, 1980). In solutions of high ionic strength 
(0,4 - 0.6M KCl) the predominant form is 48. It has been proposed
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that the 4S is the functional receptor while the 8S, an aggregate of 
the 4S, serves to maintain the pool of 4S (Powell - Jones et al. 1975),
In contrast, Wittlif has repeatedly proposed that the 8S receptor is 
the active form, and only breast tumours containing this form can be 
oestrogen dependent (Wittlif & Savlov, 1975 ; 1978; Wittlif e;t aJ, 1976; 
Savlov ^  aJL, 1977 ) though most groups have failed to find any correlation 
between the molecular form of the oestrogen receptor and hormone 
dependence (Jensen e;^  a_l, 1975; Dao & Nemoto, 1980; Freedman & Hawkins, 
1980). Many of the problems regarding the size, and distribution of 
sizes, appear to indicate that the form of the receptor isolated is 
very dependent on the methodology used. Additionally, because of 
salt and protein dependent aggregation phenomena, it is not possible 
to clearly define the size(s) of soluble receptor ijn vivo.
The presence of the oestrogen receptor is used to indicate that 
a breast tumour is dependent on oestrogen for growth (Section 1.11).
The standard method for measurement of cytoplasmic or soluble oestrogen 
receptor is to occupy unfilled receptors and to exchange endogenously 
bound hormone for radioactive hormone and then absorb unbound hormone 
onto dextran coated charcoal (Schrader & O'Malley, 1972; Peck & Clark, 
1977; King e^ aG, 1979) or absorb the labelled receptor to glass pellets 
(Clark & Gorski, 1965 ) hydroxylap atite (Erdos et 1970) or DEAE
filters (Santi et aJL, 1973), More recently attempts have been made 
to develop an oestrogen receptor assay suitable for small amounts of 
tissue, such as needle biopsies (Section 5.6) and one of the most 
promising utilizes isoelectric focusing (Gustafsson e^t 1978;
Lloyd et al, 1982), Other possibilities suggested have been monoclonol 
antibodies (Greene & Jensen, 1982) and cyto- and histo- chemical methods
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(Chcuaness 1980) although there is much debate about the
reliability of these methods (see Section 5.6).
1.8 TRANSLOCATION / ACTIVATION
The two step mechanism proposes that the binding of oestrogen to the 
receptor allows the translocation of the hormone receptor complex into 
the nucleus. The temperature sensitive 'activation' (Williams &
Gorski, 1971) or addition of an extra 50,000 molecular weight polypeptide 
(Notides & Nielson, 1974; 1975; Thampan & Clarl^ :, 1981) was thought to
change the shape of the hormone receptor complex and allow its passage
into the nucleus. This activation causes a change in the sedimentation 
coefficient from 4S to 5S in salt containing sucrose density gradients 
(Notides & Nielson, 1974; 1975; Weichman & Notides, 1980), The activated
or 5S form can be distinguished from the 4S by use of bovine serum
albumin (BSA), which sediments between the two forms on sucrose density 
gradients. Activation of the hormone receptor complex increases its 
affinity for DNA or DNA cellulose (Fleischmann & Beato, 1979; Gschwendt 
& Kittstein, 1980). Activation of steroid receptors can be achieved 
in a number of ways, by increasing the ionic strength (Gschwendt & 
Kittstein, 1980; Weichman & Notides, 1980) or increasing the pH 
(Bailly e;t al, 1978) or by dilution, filtration or dialysis to remove 
a low molecular weight inhibitor (Sato et 1980; McDonald & Leavitt,
1982).
Originally Williams & Gorski (1971) r^orted that activation was 
temperature sensitive, though more recently Pavlik e^ ^  (1979) and 
Traish ^  ai (1977) have reported activation at low temperature.
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There is presently disagreement on whether activation takes place in 
the cytosol (Jensen & De Sombre, 1972; O'Malley & Means, 1974) or in 
both the nucleus and cytoplasm (Linkie & Siiteri, 1978). This latter 
suggestion compliments the revised model of steroid hormone action 
proposed by Martin & Sheridan (1982). This disagreement is further 
complicated by reports that the two processes 1) activation (increased 
affinity for DNA) and 2) transformation (change from 4S to 5S)actually 
occur as independent steps (Bailly e^ al, 1980; Gschwendt & Kittstein, 
1980),
1.9 NUCLEAR BINDING
1.9.1 THE NUCLEAR OESTROGEN RECEPTOR
The concentration of receptor-bound steroid by the nucleus was one of 
the first observations in the study of steroid-receptor interaction 
(Noteboom & Gorski, 1963; King & Gordon, 1966; Jensen et al, 1968).
The binding of oestrogen receptor complex to the appropriate nuclear 
sites triggers the genetically mediated biological response. The 
hormone/receptor complex must be retained in the nucleus for periods 
longer than 6 hours to induce a full oestrogenic response (Clark & Peck, 
1976; 1979). It is widely believed that the binding of the nuclear 
receptor complex causes a change in the gene structure permitting access 
(at the initiation sites) to the enzymes responsible for transcription. 
This is demonstrated by the appearance of puffs, indicating gene 
transcription, on the Drosophila polytene chromosomes of larval salivary 
glands resulting from ecdysterone binding (Groenraeyer & Pongs, 1980) 
and by the increased sensitivity of vitellogenin genes to nuclease 
digestion, after oestrogen treatment (Gerber - Huber et ad, 1981).
Horwitz & McGuire (1978 a ; b) first reported the rapid loss, subsequent 
to translocation, of 70% of the total cellular receptor in MCF-7 cells. 
This rapid loss of nuclear receptor, now termed nuclear receptor 
processing, was shown to correlate quantitatively with the induction 
of the progesterone receptor. Actinomycin D, and other drugs which 
intercalate between G-C base pairs, but neither A-T intercalating 
drugs nor RNA synthesis nor protein synthesis inhibitors, prevent 
processing. Horwitz & McGuire (1980) concluded that this inhibition 
of processing resulted from the direct effect of actinomycin D on DNA 
conformation. Processing does not occur, or only occurs at a reduced 
rate, in response to antioestrogens in rat uterine cells (Pavlik £t al, 
1979; Kassis & Gorski, 1981). It has been recently suggested that 
processing of nuclear receptor coincides with the appearance of salt 
resistant nuclear receptor, (Kasid et a^, 1982; Strobl jet ad, 1982) - 
the fraction which was proposed by Clark and Peck (1976 ; 1979) to 
control the genetic response to oestrogen.
Auricchio's group have repeatedly proposed (Auricchio ej^  1981;
Migliaccia & Auricchio, 1981) that the oestrogen receptor is controlled 
by phosphorylation and that processing is the dephosphorylation of the 
nuclear receptor. Although there is little evidence of phosphorylation 
of steroid receptors vivo (Grody ejt 1980) control of other
nuclear proteins, such as RNA polymerase (Dahmus, 1981), histone and 
non-histone proteins (Langan, 1978; Isenberg, 1979), by phosphorylation 
has been reported.
There are also two types of oestrogen binding in the nucleus, referred to 
as nuclear type I and nuclear type II (Eriksson et al, 1978; Markaverich
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et al, 1980). The nuclear type I is the classical nuclear receptor 
which results from the translocation of the cytoplasmic receptor.
The nuclear type II binding is also hormone and tissue specific,
exhibits a lower affinity for oestrogen than the type I receptor but
is not related to the cytoplasmic type II binding (Markaverich e;t al, 
1980).
The function of nuclear type II is unknown but Kelner & Peck (1981) 
claim that it is absent in tissues such as the pituitary and hypothalamus, 
which contain oestrogen receptors but do not grow and divide in response 
to oestrogen.
The size of the classical nuclear receptor is generally accepted as 5S
but a large percentage of 4S receptor has been found in purified nuclei
(Linkie & Siiteri, 1978; Bailly e;^  1980). The nuclear oestrogen
receptor from oviduct has been partially purified (Schneider & Gschwendt,
1980). The steroid nuclear receptor which has been best characterised 
is the progesterone receptor (Schrader et al_, 1981) which consists of 
2 subunits, A and B, both of which bind progesterone and which have 
been purified to homogeneity (Schrader eù 1977; Coty ^  al, 1979).
The A subunit shows DNA binding activity which is masked in the native 
form and which is exposed only upon a conformational change or upon 
its dissociation from the larger complex.(O'Malley e^ aG, 1972; Coty 
et al, 1979). Protein B does not show DNA binding activity but appears 
to interact with chromatin at specific sites (Schrader ^  1972).
The native form has been shown to contain equal amounts of the A and B 
subunits (Birnbaumer et 1979).
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The main methods of measuring nuclear oestrogen receptors are based 
on the exchange assays described by Anderson ^  a_l (1972). This 
involved the exchange of unlabelled hormone, bound to the receptor, 
with labelled oestrogen during an incubation at 37°c. The conditions 
of incubation have been altered, by various groups in an attempt to 
maximise the extent of hormone exchange and minimise the digestion of 
the receptor by protease action (Garola & McGuire, 1977a). Modifications 
of the assay include salt extraction of the receptor and the measurement 
of binding by receptor precipitation using protamine sulphate (Chamness 
et al, 1975), ammonium sulphate or hydroxylappatite (Garola & McGuire, 
1977b).
1.9.2 NUCLEAR ACCEPTOR SITES
The concentration of receptor in the nucleus may reflect the hydrophilic 
nature (see Section 1.10) of the steroid receptor complex (Williams & 
Gorski, 1974; Sheridan et aG, 1979) though a great deal of evidence 
has accumulated which suggests that about 90% of filled receptor is 
associated with chromatin (Spelsberg, 1974; Heraminiki, 1976). This 
led to the controversial suggestion of specific acceptor sites, for 
the hormone receptor complex, distributed throughout the chromatin 
(Chamness et 1974; Duller et ad, 1975). The main disagreement
is on whether receptor binding to purified nuclei is a saturable process 
(Higgens et al, 1973b; Andre & Rochefort, 1975) although Yamamoto & 
Alberts (1974 ; 1975) claim that specific sites could be masked by the 
vast excess of low affinity binding to DNA.
Reports have failed to agree on whether the acceptor sites are
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distributed throughout the chromatin (Spelsberg et ad, 1975) or 
concentrated in the 'inactive* (heavy) (Sala - Treoat.et al 1977; Socher 
et al, 1976) or 'active' (light) (Stratling and O'Malley, 1976;
Heraminiki & Vauhkonen, 1977) fraction of the chromatin. The response 
to hormone stimulation (Frenster et al, 1963; Webster et al, 1976) has 
traditionally been associated with the light chromatin. Fractionation 
of chromatin using nuclease dissection led to the suggestion that 
acceptor sites are well distributed throughout chromatin (Massol 
et al, 1978; Senior & Frankel, 1978). Davies e^ ad (1980) found that 
the transcriptionally inactive portion of chromatin contained 2 - 3  
times as many acceptor sites although these sites had a lower affinity 
for hormone receptor complex than those in the transcriptionally active 
fraction.
At some stage each component of the nucleus has been proposed as the 
acceptor due to its isolation in association with the steroid/receptor 
complex, e.g. ribonucleoproteins (Liao et al, 1973; Laing & Liao, 1974) 
the nuclear envelope (Jackson & Chalkley, 1974 a ; b; Smith & Von Holt,
1981), nuclear matrix (Barrack & Coffey, 1980) histone proteins (King 
& Gordon, 1967; sluyser, 1969) non-histone protein (King & Gordon, 1972; 
Puca et al, 1974; Mainwairing et 1976; Thrall et ad, 1978) and DNA
(Higgens et ad, 1973 a ; Yamamoto & Alberts, 1974 : 1975).
It is likely that DNA is an essential component of a three dimensional 
acceptor site but not the exclusive determinant of steroid receptor 
complex binding, since protease treatment releases-receptor (King & 
Gordon, 1972) and the binding of receptor to DNA is of low affinity 
and unsaturable (Williams, 1974; Duller & O'Malley, 1976). Until
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recently no difference in the affinity of the receptor complex for 
homologous or heterogenous DNA could be found (Yamamoto & Alberts,
1974). But recently,regions of DNA, cloned from hormone responsive 
genes, have been isolated from the chick oviduct which exhibit a 
higher affinity for the progesterone receptor than does bulk DNA 
(Compton eit ad, 1982; Mulvihill et ad, 1982). Similar regions from 
the mouse mammary tumour virus exhibit a higher affinity for the rat 
liver glucocorticoid receptor (Payvar ejk 1981).
The second part of the acceptor activity is thought to be contained 
in the non-histone component of chromatin. A tightly bound protein 
fraction, extractable in 2M NaCl, has been found to have acceptor 
activity for the oestrogen receptor complex (Puca ejt al^ , 1974 ; 1975) 
and the androgen receptor (Mainwairing et al, 1976). So far the best 
characterised is the acceptor for the progesterone receptor (Spelsberg, 
1974). The acceptor fraction is tightly bound to DNA and is sensitive 
to- protease but not nuclease. The fraction is confined to chromatin 
but generally distributed within it, and the acceptor fraction is more 
active in target tissues than non-target tissue (O'Malley et 1972;
Chytil, 1975; Pikler ad, 1976; Spelsberg & Toft, 1976). Extraction
of histones and some non-histone proteins shows that the acceptor 
activity is present in all tissues but is masked in non target tissues 
(Spelsberg, 1974; Spelsberg et al, 1976), However, the techniques 
of tissue fractionation and reconstitution, used by Spelsberg's group, 
have been heavily criticised by a number of groups (Zasloff & Felsenfeld, 
1976; Fulmer & Fasraan, 1979; Stein, 1979).
Spelsberg (1976) and Weichman & Notides (1980) found that there were
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three distinct classes of acceptor sites for the oestrogen receptor
i) the higher affinity sites (100 sites/cell) with a dissociation 
constant (Kd) of 10 so that these sites would be completely 
filled at physiological plasma steroid concentration.
ii) intermediate affinity acceptor sites (900 sites/cell) with a Kd 
of a 5 X 10 in chick oviduct which are probably involved in
fine genetic control.
iii) lowest affinity acceptor sites (4000 sites/cell) with a Kd of 
1 X 10 which are partially, but not all filled, at high 
concentrations of plasma oestradiol and their function is not 
fully defined.
In order to obtain the full spectrum of physiological response, all 
the middle class sites and a proportion of the lower affinity sites 
must be filled. Spelsberg has suggested that the majority of these 
sites must be filled. Furthermore Thrall ei^  ad, (1978) also 
reported three classes of acceptor sites for the progesterone receptor 
but which were present in a higher concentration per cell. However 
both studies report the total number of acceptor sites to be in excess 
of the 1000 - 2000 sites per cell that Clark & Peck (1976) calculated 
must be filled in order to get a full physiological response.
1.10 PROBLEMS IN THE TWO STEP MECHANISM
Recently doubts have been expressed on the validity of the two step 
mechanism. One flaw has been the discovery of unoccupied nuclear 
receptors in the cell-line MCF-7 and in three other cell lines from 
pleural effusions (Zava & McGuire, 1977; Horwitz & McGuire, 1978 a & b) 
The unoccupied nuclear receptor was thought to be responsible for the 
ability of these cell lines to grow in the absence of oestrogen.
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Reports followed of a large number of breast cancers containing empty 
nuclear receptor (Garola & McGuire, 1977b; Panko & McLeod, 1978;
Thorsen, 1979). Panko & McLeod (1978) proposed that the proportion 
of tumours containing unoccupied nuclear receptor corresporded to the 
proportion which contained receptor but which failed to respond to 
endocrine therapy. But, more recently, unoccupied nuclear receptor 
have been detected in immature rat (Carlson & Gorski, 1980), rat uterus 
and hypothalamus (Thrower al, .1981) normal and malignant human 
endometrium (Levy ejt ad, 1980; Geier et al, 1980) human myometrium 
(Giannopoulos et 1980), chick oviduct (Mester & Baulieu, 1972) and
purified uterine nuclei from pigs (Jungblut e;t a3^ , 1978), This 
suggested that unoccupied nuclear receptor was a product of the normal 
mechanism of oestradiol action in its target tissue. Recently Geier
ad (1982) have correlated the appearance of unoccupied nuclear receptor 
with a decrease in cytoplasmic receptor after exposure to oestrogen.
There have been many unsuccessful attempts to detect a weakly bound 
ligand, such as oestriol or oestrone, a metabolite of oestradiol or an 
adrenal analogue, which could be responsible for translocating the 
apparently empty receptor to the nucleus.
Estimates of the proportion of nuclear receptor that is uncharged have 
varied from 75% for MCF-7 (Horwitz & McGuire, 1978b) to 9 - 37% for human 
endometrium (Geier at 1980), One reason for the great variation
may be that the method of tissue preparation profoundly affects 
the number and distribution of empty receptors detected (Clark & Peck, 
1979; Martin & Sheridan, 1980).
Another possible reason for the inaccuracies in estimates cf unoccupied
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nuclear receptor levels may be the assumption, in most reports, that 
there is no exchange at 4°c, despite evidence against this in the 
original work by Anderson et al, (1972) and more recently by Blankenstein 
e;t ad (1979) and Leake (1981b), Recently McGuire's group have claimed 
that unoccupied nuclear receptors in MCF-7 were an artefact resulting 
from cytoplasmic receptor adhering to the nucleus, and these receptors 
could be removed by purification of the nuclei through sucrose (Edwards 
et ad, 1980a), In reply Geier e^ ad (1981) found no change in the 
level of unoccupied nuclear receptor after purification of MCF-7 nuclei.
Much of the work in detecting unoccupied nuclear receptor has involved, 
as a first step, salt extraction of the receptor. There is still 
disagreement on whether the biologically functional nuclear receptor 
estimated at 20% of the total nuclear receptor, is contained in the 
60% - 70% (Clark & Peck, 1979) viiich can be salt extracted. Many 
investigators have shown the presence of salt insoluble or resistant 
nuclear receptor in a number of systems, such as oestrogen receptor in 
rat uterus (Puca & Bresciani, 1968; Master & Baulieu, 1975), chick liver 
(Lebeau ^  al, 1973) and human endometrium (Katzenellenbogen ^  1980)
and the androgen receptor from rat prostrate (Hiremath et al, 198].; Mulder 
et ad, 1981). The 4S or cytoplasmic receptor has been detected in the 
nucleus (Linkie & Siiteri, 1978; Bailly et al, 1980), This disagrees 
with the proposal that activation and transformation to 53 are pre­
requisites of receptor entry into the nucleus. This problem is 
complicated by an incomplete understanding of the mechanism of activation 
and transformation (Bailly et 1980; Gschwendt & Kittstein, 1980).
Translocation may only be the passive movement of the receptor to the 
nucleus driven by the greater free water concentration of the nucleus
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(Horwitz & Moore, 1974). Sheridan e_^  (1979 ; 1981) maintain that
the distribution of receptor as proposed in the two step mechanism is 
a result of the methods used to prepare the sub-cellular fractions. 
Sheridan proposes that receptors are in equilibrium between the cytoplasm 
and the nucleus and appear only in the soluble or cytoplasmic portion 
due to the large volume of buffer, relative to tissue volume, used in 
both the homogenisation step and the subsequent purification of nuclei. 
The conclusions of Sheridan e^ al^  (1979, 1981) and the resulting new 
model of steroid action (Martin & Sheridan, 1982) seem convincing despite 
their use of crude nuclear pellets (subject to cytoplasmic contamination) 
and of autoradiography (subject to visual and fixation artefacts).
However Pietras & Szeg:cp (1977 ; 1979) believe that the cytoplasmic 
receptor in intact cells actively resides in the plasma membrane.
This latter view would explain how steroid from the processed nuclear 
receptor complex can be excreted from the cell without recombining with 
empty soluble receptor.
1.11 BREAST CANCER THERAPY AND ITS RELATION TO OESTROGEN 
RECEPTOR STATUS
Breast cancer can be treated by radiotherapy, chemotherapy, immunotherapy 
and hormone therapy or some combination of the four (U.S. Dept, of Health, 
1980). Once a malignant breast tumour has been detected and removed 
by surgery, with or without radiotherapy, one of the main problems is 
the selection of the treatment most suitable to prevent or control 
secondary disease.
The first properly documented use of hormone therapy was in 1896 by 
George Beatson when he induced regression of inoperable breast tumours
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as a result of oopherectomy in some pre-menopausal women. In the 
intervening period it has been confirmed that only 25 - 30% of patients 
with advanced breast cancer experienced objective remission as a 
result of hormone therapy. Folca e^ (1961) began to provide
some explanation, when they administered labelled hexoestrol to breast 
cancer patients about to undergo adrenalectomy and found a response only 
in patients whose tumours concentrated ]a rge amounts of label.
The first studies on cytoplasmic oestrogen receptors in breast tumours 
reported that 80% of oestrogen receptor positive (ER+) patients and 
10% of those without receptor (ER-), responded to endocrine therapy 
(Jensen et 1975; Engelman et 1975; McGuire ejt 1975),
A more realistic figure for the response rate of ER+ patients seems 
to be 40 - 60%.(Byar e^ 1979; Edwards et ad, 1979; Hawkins et al,
1980). Even this figure is much more accurate than predictions based 
on clinical data (such as menopausal status, age, parity, disease free 
interval and sites of known secondaries) (Stoll, 1977).
The successful response of some receptor negative patients to hormone 
therapy may be explained either as (A) physiologically ER+ tissue in 
which the receptor was destroyed during 1) post-operative handling or
2) pre-operative therapy or (B) a response mediated by an indirect 
pathway eg. tamoxifen normally classified as an antioestrogen can also 
act by inhibition of prostaglandin synthetase (Tisidale, 1977) or 
(C) an assay error arising if the biopsy was atypical of the whole 
tumour and contained no, or a very low number of, tumour cells relative 
to fat and connective tissue.
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The existence of ER+ patients that do .not respond may be due to the 
detection of non-functioning oestrogen receptor, The receptor may 
fail to function because it cannot translocate to the nucleus or because 
it cannot bind to the appropriate acceptor sites. The number c£ ER+ 
patients that do not respond decreases when the nuclear receptor content 
is also assayed as an indication of which tissues contain «functional 
receptor*. This additional assay detects where the receptor 
translocation mechanism is defective (Laing al^ , 1977).
It has been reported that assaying for a product of oestrogen action 
also improves the response rate because it should indicate that the 
receptor system is able to induce a genetic response. Products that 
have been used in this way are casein mRNA (Rosen & Socher, 1977), 
cK lactalbumin (Woods e^ 1979; Hall at 1979), peroxidase (De
Sombre ejt 1978; Cantwell et al, 1980; Duffy & O'Connell, 1981),
and the progesterone receptor (McGuire ^  1976; Asselin & Labrie,
1978), The latter has become the most popular marker but synthesis 
of the progesterone receptor is not a complete guarantee of hormone 
dependence. Rat mammary tumours have been reported in which oestrogen
and progesterone receptors are present but which are hormone independent. 
(McGuire, 1978; Allegra e_t 1979), Barnes ^  a ^ . (1979) have r^orted
breast tumours which contain progesterone receptor but no oestrogen 
receptor. While oestriol has been shown to induce progesterone receptor 
but not DNA synthesis (Clark & Peck, 1979), or subsequent growth responses
Westley & Rochefort (1979) have suggested that three intracellular 
proteins resulting from oestrogen stimulation, which are inhibited 
by tamoxifen, may prove to be better markers.
A tumour may contain a mixed population of ER+ and ER- cells. In this 
case response to endocrine therapy would be short term, until only the 
hormone independent cells are left (Sluyser & Evers, 1975). There 
is some evidence that tumours de-differentiate as they age since 
hormone dependent tumours Wiich are serially transferred to iimnuno- 
suppressed rats eventually become autonomous. Human breast tumours 
which initially responded to endocrine therapy but eventually progressed 
to an apparently unresponsive state have been reported (Stoll, 1977; 
Leake e^ al, 1981a), It is not known whether, at the time of death, 
all métastasés have become receptor negative (and so hormone indpendent) 
or if they retain receptor but no longer respond to endocrine therapy.
It is now generally accepted that hormone status of a tumour may be 
of prognostic value since, after stratification according to the extent
of nodal involvement, patients with receptor positive disease have, 
on average, both a greater disease free interval before relapse and a 
longer total survival time than receptor negative patients (Hawkins 
et al, 1980; Leake, 1981a), This indicates that receptor positive 
tumours are generally slower growing. One reason for this may be that 
receptor negative tumours are less well differentiated and hence more 
aggressive. Early attempts at relating receptor status to histology 
showed no correlation (Feherty e^ aT, 1971; Leclerq e^ a^, 1973) though 
more recent, and possibly more careful, studies have found well 
differentiated tumours more likely to be receptor positive (McCarty
a]., 1980; Pari & Wagner, 1980). Use of elastosis content and other 
histological parameters may be of value, but only when all tumours 
are classified by a single pathologist (Mills, 1980; Rolland et al,
1980).
1.12 OBJECTIVES
The object of this work is to study and compare the two standard methods 
used to measure nuclear oestrogen receptors. The conditions which 
influence the binding of œstrogens to the nuclear receptor will be 
examined in detail in an effort to explain some of the anomalies 
present in the literature about nuclear receptor stability and function. 
In particular, the exchange rate of the nuclear receptor at low 
temperature will be thoroughly assessed since it is on this method 
that the presence of the controversial unoccupied nuclear oestrogen 
receptor is dependent. In addition the practice of salt extracting 
nuclear receptor prior to its study will be evaluated, in view of 
recent criticisms that either the extracted fraction represents a 
non-functional complex, or that only a variable and inadequate 
proportion of the nuclear receptor is recovered by this technique.
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2 . MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 FINE CHEMICALS were obtained as follows;-
Sigma, LondonBovine serum albumin 
(fraction V)
Deoxyribonucleic acid (DNA) 
(calf thymus type V sodium 
salt, highly polymerized)
Monothioglycerol
Norit A (activated charcoal)
Phenyl methyl sulphonyl 
fluoride (PMSF)
DIT (dithiothreitol)
Sigma, London
Sigma, London 
Si gma, Lo ndo n 
Sigma, London
Boehringer Corporation (London) Ltd,
N-2-hydroxypiperazine -N'-2-ethane Boehringer Corpcration (London) Ltd, 
sulphonic acid (HEPES)
Triton X-100 (purified)
Trasylol (Aprotinin in isotonic 
solution containing 0.9% 
benzyl alcohol)
Hydroxylap atite - spheroidal 
(HAP)
Koch-Light Laboratories, Colnbrook 
Bayer, Germany
BDH, Dorset
All other chemicals used were, wherever possible AnalaR grade reagents, 
supplied by BDH Chemicals Limited, Poole, Dorset.
2.1.2 STEROIDS
(6,7-(^H)) Oestradiol-17^ (40-80 Ci mmol ^) and (2,4,6,7-(^H)) Oestradiol-1'^ 
-1( 100-120 Ci mmol ) were obtained from Amer sham International, England 
and tested for purity on an LH20 column. Unlabelled Cestradio 1-17/5^  
and Diethylstiboestrol (DES) were obtained from Sigma, London.
2.1.3 SCINTILLAT ION MATER lALS
Toluene (AR grade), 2,5 diphenyloxazole (PPG) and 1,4 di (2-(5- 
phenyloxazolyl))-benzene (POPOP) were obtained from Koch-Light 
Laboratories, Colnbrook, England, Triton X-100 was obtained from 
Rohm and Haas, Croydon, England and purified with silica gel prior to 
use.
2.1.4 HUMAN TISSUE
Breast tumour tissue and human endometrium were kindly supplied by 
Hospitals of the Greater Glasgow and Ayrshire Health Boards principally 
Stobhill General Hospital, Western Infirmary, Gartnavel General Hospital, 
Hairmyres Hospital, East Kilbride and Ballochmyle Hospital, Mauchline, 
Ayrshire.
2.1.5 MI SCELIANEOUS
Sterile plastic pots used for human tissue collection were obtained 
from Sterilin Ltd., Teddington, England.
Glass microfibre filter discs (GF/C 2,5cm diameter) were obtained from 
Whatman Ltd., England,
Glass/glass tissue grinders were obtained from Kontes, U.S.A. or Cowie 
Scientific, Midd 1 esborough, England.
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Glassware was washed and rinsed in glass distilled water as the assay 
of receptor was found to be adversely affected by the presence of 
divalent metal ions (Laing, 1980), All solutions were made up in 
glass distilled water.
All glassware contaminated with human tissue was soaked overnight in 
chloros, rinsed and then washed.
2.2 METHODS
2.2.1 TISSUE HANDLING
Tissue was obtained fresh from the operating theatre in an empty 
sterile container and transported on ice to the laboratory. When 
tissue was not used fresh it was stored, up to 4 weeks, at ~20°c in 
sucrose-glycerol buffer (0.25M sucrose, 1.5mM MgCl^, lOmM HEPES 
(pH 7.4)50% (v/v) glycerol). Before use the tissue was rehydrated 
in 0.25M sucrose, l.SmM MgCl^, lOmM HEPES (pH 7.4) at 0°c for 15 
minutes. The oestrogen receptor remains stable in both concentration 
and molecular form for at least three months under these conditions 
(Hyder & Leake, 1982).
Only breast tumour tissue which had been shown to contain oestrogen 
receptor in both the cytoplasm and nucleus was used. Endometrial 
samples were taken from women undergoing uterine curettage or hysterectomy 
for benign gynaecological conditions. When necessary, two to five 
endometrial biopsies were pooled for each experiment. A portion of 
tissue, adjacent to that used for experi ments, was sent for a pathology 
report.
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2.2.2 ASSAY OF OESTROGEN RECEPTOR
The oestrogen receptor content of the cytosol and nuclear fractions 
was assayed by the method of Laing et al, (1977). Briefly, a 
competition assay was used involving 7 concentrations of ( H)-oestradiol+ 
100 fold di ethyls tijboestr ol, as a competitor. Approximately 150mg 
of tissue was homogenised by Kontes-Duall glass/glass grinder at 50mg/ml 
in sucrose buffer containing 0.25M dithiothreitol. The horaogenate 
was then separated into soluble and nuclear fractions by centrifuging 
at 5000g for 5 minutes at 4°c. The crude nuclear pellet was washed 
three times with buffered saline. Both fractions were then incubated 
with 7 concentrations of (^H)-oestradiol (between 10 ^^4 - 10 ^M)t 100 
fold diethylstiboestrol for either 18 hours at 4°c or 2 hours at 20^c. 
After incubation, unbound steroid was removed from the cytosol with 
activated charcoal (OfXB%(w/v)) and from the nuclear pellet by trapping 
on a millipore filter and repeated washing with saline (total volume 
15ml). Receptor affinity and concentration were calculated by Scatchard 
analysis using the established criteria. Briefly, a tissue was defined 
as receptor positive if three criteria were fulfilled, if 1) it yielded 
an unambiguous Scatchard plot, producing a straight line, 2) it yielded 
a Kd in the range 0.5 - 5.0 x 10 mol, 3) specificity was established 
by competition with excess DES (Cowan & Leake, 1982). Cells from 
pleural effusions and from tissue culture were assayed in a similar 
manner except that cells were disrupted by 2 short (5 sec.) bursts with 
a Dawie Soniprobe at the lowest power setting.
2.2.3 PROTEIN DETERMINATION
The protein content of each cytosol preparation was determined by the
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method of Lowry e;t al^ , (1951)
2.2.4 DNA DETERMINATION
The DNA of each nuclear suspension was determined by the modification 
by Katzenellenbogen & Leake, (1974) of the method of Burton (1956),
2.2.5a RATE OF DISSOCIATION OF (^H) - OESTROGEN FROM THE 
NUCLEAR COMPLEX
Approximately 500 mg of tissue was homogenised by Kontes-Duall glass/ 
glass grinder at 50mg/ml in sucrose buffer (0.25M sucrose, 1.5mM MgCl^, 
lOmM HEPES j^ H 7.4)) and 0.25M dithiothreitol. The homogenate was 
aliquoted and incubated for 30 rain, at 37°c in 2 x 10 ^(^H)-oestradiol 
in the presence or absence of 2 x 10 M unlabelled diethylstiboestrol 
(DES), If required, a wash in 0,1% triton X-100 was included at this 
stage to remove any contaminating blood.
The homogenate was centrifuged at 5000g for 5 minutes on a Beckman 
J2-21 centrifuge at 4°c. The crude nuclear pellet was then washed 
three times with buffered saline to remove unbound steroid and then 
resuspended in the original volume of sucrose buffer +10% (v/v) glycerol. 
A glass/glass grinder was then used to ensure a homogeneous nuclear 
suspension. At various time points, throughout the experiments, nuclear 
integrity was checked by phase contrast microscopy on an Olympus IM 
phase contrast microscope.
—7
The nuclei were incubated for 24 hours in 2 x 10 M unlabelled oestradiol, 
Duplicate (100 p.1) aliquots were removed at various time points.
At 24 hours a 2ml aliquot was removed from each flask, to determine 
the amount of receptor remaining intact.
At each time point the duplicate 100 pi aliquots were added to 5ral
0.15M NaCl. The sample was then poured down the chimney of a millipore
filter apparatus onto a pre-wetted glass fibre filter. The chimney
was washed with 20ml saline, under suction. The filter was then
removed to a plastic scintillation vial prior to drying overnight at
60^0. 10ml toluene/PPO (5g/litre) scintillant was added and the
samples counted at 30% efficiency in a Searle Mark III Liquid Scintillation
analyser.
2.2.5b ESTIMATION OF RECEPTOR REMAINING AFTER EXCHANGE ASSAY
The concentration of nuclear oestradiol receptor which remained at
the end of an exchange assay was measured in order to demonstrate
that the decrease in specifically bound oestradiol was due to exchange
of bound hormone and not degradation of the hormone-receptor complex
by protease or nuclease action. At 24 hours a 2ml aliquot was removed
from each flask, centrifuged at 5000g for 5 min, at 4°c, washed three
times and resuspended in sucrose buffer +10%(v/v) glycerol. The nuclei
-9 3were then incubated in 2 x 10 M ( H) oestradiol with or without
-7 o2 X 10 M unlabelled DES for 2 hours at 20 c. Two 100 pi aliquots
were removed and bound oestradiol determined as described above. DNA
assays were performed on 1ml aliquots removed at 24 and 26 hours.
The concentration of nuclear receptor at the start and completion of
the experiment was calculated and compared.
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2.2.6 PURIFICATION OF NUCLEI
After labelling and washing the 5000g pellet was resuspended in 1ml 
of sucrose buffer and layered over 12.5ml of 2.3M sucrose containing 
1.5mM MgClg and lOmM HEPES at pH 7.4. Tubes were then centrifuged 
in an SW-40 rotor at 105,000g for 1 hour at 4°c. The pellet was 
resuspended in the original volume of sucrose buffer containing 10%(v/v) 
glycerol. Nuclear integrity was checked by phase contrast microscopy 
before and after the 24 hour incubation.
2.2.7 SALT EXTRACTION OF NUCLEAR RECEPTOR
The labelled and washed 5000g nuclear pellet was resuspended in 6 
volumes of sucrose buffer made 0.6M in KCl and 0.25mM dithiothreitol.
The nuclear oestrogen was extracted for 60 minutes at 4°c, with 
vortexing every 15 minutes (Garola & McGuire, 1977b). The supernatant 
nuclear extract was obtained after centrifugation at 105,000g for 
30 minutes at 4^c. Pellets were resuspended in sucrose buffer and 
salt resistant receptor measured by trapping nuclei on millipore 
filters (as described above). Crude extraction of radioactivity with 
ethanol yielded the same mean values of specifically-bound oestrogen, 
or salt resistant receptor but were subject to a much higher non-specific 
background.
2.2.8 HYDROXYLAPPATITE ASSAY OF NUCLEAR OESTROGEN RECEPTORS
Oestrogen receptors were precipitated from the nuclear extract by
hydroxylappatite (HAP) as described by Garola & McGuire (1977b) and
Clark & Peck, (1979) except that HEPES buffer and dithiothreitol 
replaced TRIS buffer and monothioglycerol. The nuclear extract was 
diluted with phosphate buffer to produce a final protein concentration 
between 0,4 and 1,0 mg/ml and aliquoted into 200 jul units, A HAP 
slurry was prepared with a packed/liquid volume ratio of approximately 
0,7 as described by Williams & Gorski, (1974), 250 jul of HAP slurry
was added to the nuclear extract. The mixture was incubated on ice 
for 30 minutes and vortexed every 10 minutes to allow the receptor to 
absorp onto the HAP, The mixture was then centrifuged for 5 minutes 
at 800g and the supernatant discarded.
3
2.2.9 RATE OF DISSOCATION OF ( H) OESTRADIOL FROM SALT 
EXTRACTED RECEPTOR
The HAP bound nuclear receptor was then resuspended and incubated in 
sucrose buffer +10%(v/v) glycerol plus 2 x 10"^M oestradiol for varying 
times up to 24 hours. At each time point, three samples were washed 
twice with O.IM phosphate buffer pH 7.4 and then extracted overnight 
in 2ml ethanol.
2.2.10 CHARCOAL TREATMENT OF RADIOACTIVE OESTRADIOL RELEASED 
FROM HYDROXYLAPPATITE
After incubation the HAP bound nuclear receptor was removed by pelleting 
HAP by centrifuging at 800g for 5 minutes. In order to determine 
whether the steroid was bound to receptor or free in solution, the 
supernatant was treated with charcoal,
500 pi 0.5% dextran coated charcoal solution (DCC), 0.5% w/v Norit A
charcoal, 0.005% w/v dextran T70 in 0.25M sucrose, 1.5mM EDTA, lOmM 
HEPES ^H 7.4)is added to 1ml of supernatant and the tubes mixed.
The charcoal stripping was continued for 15 minutes at 0°c with 
periodic mixing of the tubes. After the incubation, the charcoal 
was pelleted by centrifugation at lOOOg for 5 minutes. 750 pi was 
removed to a scintillation vial and counted in triton toluene 
scintillant. Totals were calculated by counting 200 pi of untreated 
supernatant.
3. RESULTS
3.1 EXCHANGE RATE OF OESTROGEN FROM THE NUCLEAR RECEPTOR
Fig, 3.1 shows the theoretical basis of the measurement of exchange 
of oestradiol from the nuclear receptor. The first incubation at 
37°c fills all the nuclear receptor with labelled oestradiol. The 
first incubation uses homogenised tissue to maximise labelling of the 
receptor,use of tissue slices resulted in a failure to label all the 
receptor (especially in breast tumour tissue) even at 37°c. In the 
second incubation the labelled nuclei are incubated in a hundred fold
3
excess of unlabelled oestradiol. Any ( H) oestradiol which dissociates 
the nuclear receptor is then replaced by unlabelled oestradiol 
causing a decrease in specifically bound radioactivity but maintaining 
the stability of the oestrogen receptor complex. The purpose of the 
third incubation is to demonstrate, by relabelling the nuclear receptor, 
that dissociation and not degradation of receptor complex has been 
responsible for the decrease in specifically bound counts. The 
calculation of specifically bound oestradiol is illustrated in Fig. 3.2. 
This involves subtracting the non-specific counts (labelled in the 
presence of a one hundred fold excess of DES) from the total counts 
(specific and non-specific binding, labelled by ( H) oestradiol alone).
Fig. 3.3A demonstrates the effect of temperature on the exchange or
3
•off-rate* of ( H) oestradiol from the nuclear receptor bound to nuclei 
from human endometrium. There is a significant rate of exchange at 
4°c (K^= 1.39 X 10 ^ min ^) with approximately 50% of the specifically 
bound oestradiol exchanged during the 24 hour incubation. The rate
Figure 3.1 - Theoretical Basis of Off-Rate Experiments
This shows the theoretical basis of measurement of 
exchange of oestradiol from the nuclear receptor 
(Section 2.2.5.A). The first incubation at 37^c fills 
all the nuclear receptor with labelled oestradiol. In 
the second incubation the labelled nuclei are incubated 
in a hundred fold excess of unlabelled oestradiol.
3
Therefore any ( H) oestradiol which dissociates from 
the nuclear receptor is replaced by unlabelled oestradiol 
causing a decrease in specifically bound radioactivity. 
The object of the third incubation, at 20^c in (^H) 
oestradiol, is to demonstrate that dissociation ( —  
and not degradation (---^ ) of the nuclear receptor 
complex, has been measured.
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Figure 3.2 - Off-Rate of ( H) Oestradiol from Pre-labelled Nuclear
Receptor
3
Human nuclear oestrogen receptor was loaded with ( H) 
oestradiol as described in Section 2.2.5.A. The 
off-rate is measured as a decrease in specifically 
bound oestradiol. This is calculated by subtracting
the non-specific counts ( (---- ) labelled in the
presence of a one hundredfold excess of DES as described 
in Section 2.2.5.A) from total counts ( )
specific and non-specific binding labelled by oestradiol 
a lone ).
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Figure 3.3 - The Effect of Temperature on the Dissociation of
Oestradiol from the Nuclear Receptor
Figure 3.3.A Rate of dissociation of specifically-bound oestradiol
from the human endometrial nuclear receptor. Nuclei
-9 3were prepared, prelabelled with 2 x 10 M ( H) oestradiol 
and then incubated in sucrose buffer containing 2 x 10”^M 
unlabelled oestradiol as described in Section 2.2.5.A.
The effect of temperature on the exchange rate was 
studied. Incubations were performed at O— O 4°c (30),
^ ® 20°c (9), A:-- A  37°c (2). Results represent the
percentage of specifically bound counts at the time 
indicated (Number of experiments). Experimental error 
on each point is 2 5% (within 95% confidence limits).
Figure 3.3.B Rate of dissociation of specifically-bound oestradiol
from nuclear receptor from breast tumour tissue at 4°c.
O— O (6) Nuclei were prepared and labelled as described 
in Section 2.2.5.A. Results represent the percentage cf 
specifically bound counts at the time indicated (Number 
of experiments). Experimental error on each point is 
1 5% (within 95% confidence limits).
A
- 4:3 -
1,00
80 —
60 -
40 -
20 -
K 100
80 -
60 -
T im e  (hr)
of exchange was found to increase with increasing temperature, with 
KLj^ values of 8.3 x 10 ^ min  ^at 20°c and 12,8 x 10 ^ min  ^at 37°c, 
Complete exchange occurs within 2 hours at 37°c. The rate of 
exchange was found to be identical, whether stored or fresh tissue 
was used. This was true at all three temperatures.
The rate of exchange from breast tumour nuclear receptor at 4°c was 
found to be similar to that in human endometrium. However, despite a 
slightly lower initial rate of exchange (K^= 1.18 x 10 ^ min ^ ) there 
is a greater decrease in specifically bound oestradiol over the 24 hour 
incubation. This may result from degradation of the receptor by a 
protease present in malignant but not in normal tissue. Total recovery 
of receptor at 26 hours was approximately 87% for endometrium and 
approximately 76% for breast tumour.
In order to show that the decrease in specifically bound counts was 
not due to protease degradation the incubations were performed in 
the presence of the protease inhibitors trasylol or PMSF. At 4°c 
neither of the protease inhibitors had an effect on the exchange rate, 
suggesting that the decrease in specifically bound oestradiol is not 
due to protease degradation of the receptor (Fig. 3.4A). However, 
at 20°c PMSF, but not trasylol, markedly reduced the initial exchange 
rate (Fig. 3.4B). After 24 hours the level of specifically bound 
label was similar in both the control and PMSF treated nuclei. This 
result can be explained by the fact that PMSF is an irreversible serine 
protease inhibitor which is rapidly inactivated if it does not react 
with a protease. Therefore PMSF would inactivate protease molecules 
present at the beginning of the incubation. This leads to the
Figure 3.4 - Effect of Protease Inhibitors on the Dissociation of
3
( H) Oestradiol from the Nuclear Receptor.
Figure 3.4.A Effect of protease inhibitors on the off-rate of (^H) 
oestradiol from the nuclear receptor at 4°c. Nuclei 
from human endometrial tissue were labelled and 
incubated as described in Section 2.2.5.A. Results 
represent the percentage of specifically bound counts 
retained at the time indicated. Experimental error on 
each point is t  5% (within 95% confidence limits).
Incubation medium contained no additions (O C) 2mM
PMSF (A A) (3) or 2000 units/ml Trasylol (# * ) (3)
(number of experiments).
Figure 3.4.B Effect of protease inhibitors on the dissociation
of (^H) oestradiol from the nuclear receptor at 20°c. 
Symbols as described in Fig. 3.4.A above.
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conclusion that part of the decrease in specifically bound counts at 
20°c is due to protease degradation of the nuclear receptor complex 
whereas only exchange is responsible for the decrease in specifically 
bound counts at 4°c.
Further experiments were performed to determine whether the hormone 
receptor remained intact throughout the course of the incubations.
These experiments involved relabelling the nuclei by a third incubation 
for 2 hours at 20°c in the presence of labelled oestradiol. Similar 
results could be achieved by incubating at a lower temperature for a 
longer period.
Provided no degradation of the hormone receptor has occurred then 
the level of specifically bound oestradiol at time O (the beginning of 
the second incubation) should equal the level at 26 hours (at the end 
of the third incubation). Table 3.1 shows that after the incubation 
at 4°c for 24 hours almost all the nuclear receptor from human 
endometrium can be relabelled, indicating that only exchange of hormone 
has been measured and not protease degradation. However, at higher 
temperatures a large proportion of the nuclear receptor is not relabelled 
and so has been lost during the incubation. This shows that a 
considerable portion of the decrease in specifically bound counts at 
higher temperatures (20°c and 37°c) is due to degradation of the nuclear 
receptor.
At each time point during the incubations, samples were removed and 
studied by phase contrast microscopy. A large proportion of the nuclei 
were found to have lysed during the incubation, such that less than
Table 3.1 - Re-labelling of Nuclear Receptor After Exchange Assay
3
Figures represent specifically bound ( H) oestradiol
expressed as CPM/jug DNA, mean + standard deviation
(number of experiments), as indicated in Column 1.
Nuclei from human endometrial tissue were labelled
and incubated as described in Section 2.2.5.A, After
-924 hours aliquots were re-incubated with 2 x 10 M
3
( H) oestradiol for 2 hours as described in Section 
2,2.5,.B, and the amount of specifically bound steroid 
was determined and expressed relative to the DNA 
content, measured as described in Section 2.2,4,
Temp. °C. 
(No. of Exp.)
Time (hr)
0 24 26
4°
(39) 18.8 t  10.7
10.6 2 7.0 16.2 8.1
20°
(14) 20.8 2 13.3 2.48 t. 2.5 6.0 2 4.6
37°
(2)
14.2 I 2.9 1.7 t  1.0 1.0 t  0.8
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10% remained intact at 26 hours. This problem was overcome by 
centrifuging the nuclei through 2,4M sucrose. After pétrification, 
over 90% of the nuclei remained intact at 26 hours. Although the 
extent of exchange occurring over 24 hours was identical, the initial 
rates of exchange in purified nuclei showed some differences 
(Figs. 3.5 A & B). The initial rate of exchange from purified nuclei 
at 4°c may be slightly greater because purification has reduced the 
amount of receptor leaking from damaged nuclei (since soluble receptor 
complex is less readily exchanged). The reduction in the initial 
exchange rate at 20°c may be due to removal of contaminating cytoplasmic 
proteases on purification.
The exchange rate of oestradiol from the nuclear receptor can also be 
studied by an 'on-rate' measurement. Measurement of the 'on-rate* was 
carried out in a similar fashion to 'off-rate' measurements except 
that the receptor is first filled with unlabelled oestradiol and then 
incubated with an excess of tritiated oestradiol. Fig, 3,6 shows the 
binding of oestradiol to the nuclear receptor at 4°c. This method 
of measuring the exchange rate also demonstrates that there is a 
significant exchange at 4^c (Kj^ = 7 x lO”^ min~^). However, as shown 
in the off-rate measurements, prior purification of the nuclei caused 
a change in the initial rate of exchange (K]^ = 3 x 10 ^ min  ^) but the 
extent of exchange occurring in 24 hours remained identical. This 
decrease in the exchange rate on purification of the nuclei cannot 
be attributed to removal of contaminating cytoplasmic receptor since 
this would result in an equivalent reduction in the extent of the 
exchange at 24 hours.
Figure 3.5 - Effect of Purification of Nuclei on the Exchange Rate
3
of ( H) Oestradiol from the Nuclear Receptor.
Figure 3.5.A Effect of purification of nuclei on the exchange rate
of (^H) oestradiol from the nuclear receptor at 4°Co 
Nuclei f r o m human endometrial tissue were labelled 
and incubated as described in Section 2.2.5.A. Nuclei 
were purified as described in Section 2.2.6. Results 
represent the percentage of specifically-bound counts 
retained at the time indicated. Experimental error 
of each point is ± 5% (within 95% confidence limits). 
Incubations were performed using either nuclei purified 
through 2.4M sucrose (•—— ♦) (3) or untreated nuclei
t (0— 0) (3) (number of experiments).
Figure 3.5.B Effect of Purification of Nuclei in the Exchange Rate
of (^H) Oestradiol from the Nuclear Receptor at 20^c.
Symbols as described in Fig. 3.5.A. above.
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3Figure 3.6 - Rate of Binding of ( H) Oestradiol to Nuclear
Receptor at 4°c
Nuclei from human endometrial tissue were incubated 
with unlabelled oestradiol and then labelled with
3
( H) oestradiol as described in Section 2.2.5.A. 
Results represent the percentage of specifically- 
bound counts retained at the time indicated. 
Experimental error on each point is ^ 5% (within 95% 
confidence limits). Incubations were performed 
using either nuclei purified through 2.4M sucrose 
(#" ' # ) (3) or untreated nuclei (O— -O) (5) (Number
of experiments).
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3.2 SALT EXTRACTION OF NUCLEAR RECEPTOR
In order to determine the extent to which salt extracted nuclear 
receptor can be taken as typical of total nuclear receptor the 
percentage of specifically-bound oestrogen that was extracted in 
0.6M KCl was determined. Salt resistant nuclear receptor was measured 
by trapping on millipore filters or by extracting the steroid overnight 
in ethanol. Crude extraction of radioactivity with ethanol yielded 
the same mean values of specifically-bound oestrogen in the nucleus 
as did the filter method, but was subject to a much higher non-specific 
background. Table 2 shows that 60% of the total nuclear receptor 
in human endometrium is resistant to salt extraction. Therefore, 
methods which rely on salt extraction as the first step toward assaying 
nuclear receptors begin with only a portion of total nuclear receptor.
The major method of detecting salt extracted nuclear receptor is to 
precipitate it from the salt with hydroxyla patite (HAP) and then 
exchange endogenously bound oestradiol for tritiated oestradiol.
The rate of exchange of labelled oestradiol from the nuclear bound 
to HAP was measured and the results are shown in Fig. 3.7. At 4°c, 
there is an extremely low level of exchange of bound hormone from the 
salt extracted receptor such that over 90% of the oestradiol remains 
bound after 24 hours. The rate of exchange from salt extracted receptor 
at 20^c 2,14 X 10 ^ min ^) is also lower than the corresponding
rate of exchange from receptor bound to intact nuclei (K|= 8.3 x 10 ^ 
min ^ ). This suggests that the salt extracted HAP-bound nuclear 
receptor complex is much more stable than hormone receptor complex 
bound to chromatin. A similar rate of exchange was detected in nuclear
Table 3.2 - Salt Extraction of Nuclear Oestrogen Receptor
Nuclear receptor was extracted from human endometrial 
nuclei by incubation in 0.6M KCl for 1 hour at 4^c as 
described in Section 2.2.7. Salt extracted nuclear 
receptor was measured by precipitation with HA.P as 
described in Section 2.2,8. Salt resistant nuclear 
receptor was determined either by trapping nuclear 
receptor on millipore filters or by extracting steroid 
in ethanol overnight. Crude extraction of radioactivity 
with ethanol yielded the same mean values of specifically- 
bound oestradiol which remained bound to the nucleus, 
but was subject to a much higher non-specific background.
Specifically-bound 
(^H) E2
CPM/ug DNA
Solubilised 
by 0.6M KCl
Salt
Resistant
Standard
Deviation
26-S 4.0 -4
+ 5.6
Percentage of 
specifically-bound 
(^H) E2
39.9 60.1 t  12,3
3Figure 3.7 - The Rate of Exchange of ( H) Oestradiol from Salt
Extracted Nuclear Receptor at 4^c and 20^c
Endometrial nuclei were prelabelled at 37^c with (^H) 
oestradiol (Section 2.2.5.A) and the nuclear receptor 
was extracted with 0.6M KCl (Section 2.2.7). The 
nuclear receptor was then precipitated with HAP 
(Section 2.2.8) and incubated as described in Section 
2.2.9. Results represent the percentage of specifically 
bound counts retained at the time indicated at 4°c 
(0— 0 ) (7) and 20°c (#- # ) (3) (number of experiments).
Experimental error on each point is 5% (within 95% 
confidence limits).
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receptor salt-extracted from breast tumour tissue.
However, several groups (Lan & Rutledge, 1979; Blankenstein et al, 1980) 
have reported a high rate of exchange of steroid from salt extracted 
receptor at low temperature. These groups appear to have measured 
the exchange rate from the receptor in a buffer containing high salt 
concentration. Therefore, the effect of ionic strength on the 
exchange of steroid from receptor complex was studied. Increasing 
the concentration of potassium chloride was found to increase the rate 
of dissociation of bound oestradiol from the salt extracted nuclear 
receptor (Fig. 3.8). A similar but less pronounced effect was obtained 
using sodium chloride. In order to check that dissociation of hormone 
from the receptor was responsible for the decrease in specifically 
bound radioactivity, rather than extraction of the entire hormone 
receptor complex from the HAP, the proportion of free and bound steroid 
was measured in the soluble fraction remaining after precipitation of 
the HAP. After measurement of total radioactivity present in the 
fraction, free steroid was removed by treatment with charcoal and so 
present as free steroid. This proves that increasing the salt 
concentration increases the rate of exchange and does not cause extraction 
of the receptor complex from the HAP.
The rate of dissociation of hormone from the proportion of nuclear 
receptor which was resistant to salt extraction was determined. After 
extraction of salt soluble receptor the nuclei were then incubated in 
unlabelled oestradiol and the specific binding determined by trapping 
nuclei on millipore filters. The results are shown in Fig. 3.9 and 
indicate that the rate of exchange is similar to that measured in
Figure 3.8 - Effect of Salt Concentration on the Exchange Rate of
3
( H) Oestradiol from Salt Extracted Nuclear Receptor 
at 4°c
Nuclear receptors were labelled and extracted as described 
in Sections 2.2.7 to 2.2.9. Results represent the 
percentage of specifically bound counts retained at the 
time indicated. Experimental error on each time point 
is i  5% (within 95% confidence limits). Incubation 
medium contained 0.15M Na Cl (O— ) (7), 0.4M KCl
(# ) (2), and 0.6M KCl (A— -A. ) (3) (number of
experiments). At each time point, after removal of 
the HAP bound nuclear receptor, dextran coated charcoal 
was used to show that dissociation of oestradiol had 
been measured, and not extraction of the receptor 
complex from HAP, i.e. that the supernatant contained 
free oestradiol (Section 2.2.10).
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3Figure 3.9 - The Rate of Dissociation of ( H) Oestradiol from
Nuclear Receptor Resistant to Salt Extraction
Endometrial nuclear receptor was labelled and salt 
extracted as described in Section 2.2.7 to 2.2.9.
Nuclei were resuspended and an exchange assay performed 
as described in Section 2.2.5.A. The exchange rate 
of steroid by salt resistant nuclear receptor is shown 
at 4*^ c (0— 0) (4 ) and 20^c ( )  (2) (number of
experiments). Results represent the percentage of 
specifically bound counts retained at the time indicated, 
Experimental error on each time point is t  5% (within 
95% confidence limits).
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unextracted nuclei at either 4°c or 20^c. This is further evidence 
that exchange rates measured by this method are a property of the 
native nuclear receptor and that such receptor is not, therefore, 
contaminating cytoplasmic receptor.
4. DISCUSSION
4.1 EXCHANGE RATE FROM INTACT NUCLEI
The data obtained on the exchange rate of oestradiol from the salt 
extracted nuclear receptor (Fig. 3.7) confirm the observations of 
others, (Garola & McGuire, 1977a;. Panko & Macleod, 1978; Geier et al, 
1980; Levy ajL, 1980) that there is no exchange of steroid at low 
temperature (<4^c) under these conditions. However, this result 
has been taken as evidence (Panko & Macleod, 1978; Thorsen & Stoa,
1979; Chamness & McGuire, 1980) that there is therefore no exchange 
of oestradiol at low temperature (< 4°c) under any conditions. In 
fact, the original paper on exchange of the nuclear oestrogen complex 
in rat uterus (Anderson ^  1972) showed that there was significant
exchange at 4°c within 2 hours. As can be seen in Fig. 3,3, the 
rate of exchange of oestradiol from both human breast tumour and 
human endometrial nuclear receptor complex in intact nuclei (as opposed 
to salt extracted receptor complex) occurs at a significant rate at 
low temperature. The exchange rate is such that after 24 hours 
incubation at 4^c, about half of the oestrogen binding sites (prefilled 
with unlabelled oestradiol) can be exchanged for labelled oestradiol,
A similar exchange has been described for the nuclear glucocorticoid 
receptor from rat skin (Smith et al,1982).
As would be predicted,the rate of exchange of oestradiol from the 
receptor increased with increasing temperature (Fig, 3.3 & 3.7).
Although the initial off-rate of steroid from breast nuclear oestrogen
receptor was lower than that from human endometrial nuclear receptor, 
the level of exchange taking place in 24 hours was higher in breast 
tissue than in endometrium (Fig. 3.3.A and B). Some of the apparent 
off-rate could have been due to an increased level of protease action 
in malignant tissue. Garola & McGuire (1977a) and Hyder & Leake 
(1982) have reported a high and variable level of protease activity 
in the nuclear fraction of human breast tumour tissue.
In order to determine whether the decrease in specifically bound 
oestradiol was due to protease degradation, 1) the exchange rate was 
measured in the presence of protease inhibitors (Fig. 3,4.A and B) 
and 2) the nuclear receptor was relabelled by a 2 hour incubation at 
20°c (Table 3.1). Both measurements suggest that the level of
protease is high in human tissue. However, these proteases seem to 
be relatively inactive at 4°c since most of the receptor (-^  87%) can 
be relabelled. The activity of these protease(s) can be very 
different in different human breast tumours and, in some tumours, 
may even be significant at 4*^ c (Weichman & Notides, 1977; Hyder & 
Leake, 1982). Sherman et (1981) have suggested that oestrogen 
receptor levels and molecular forms may be related to the protease 
levels, in particular to the level of plasminogen activator (known to 
be elevated in malignant disease). In the future it may be possible 
to use plasminogen activator levels as an indication of invasive 
potential and hence as a measure of the aggressiveness of tumour 
growth.
At higher temperatures there is a high level of degradation of hormone 
receptor complex, as shown by the failure to relabel all the nuclear
— 0 2  —
receptor (Table 3.1). The percentage of receptor which is degraded 
over 24 hours at these temperatures appears very high, but nuclear 
exchange assays, using elevated taaperatures, should use a much 
shorter incubation time. However, it is probable that at least a 
portion of the nuclear receptor complex is degraded even during short 
incubations at high temperatures. Katzenellenbogen e t ^ ^  (1973) 
have reported that the cytoplasmic form of the rat oestrogen receptor 
is very labile at temperatures above 20°c while Braunsberg & Pflaeger 
(1981) have reported that a portion of the nuclear oestrogen receptor 
is labile above 22°c. It is likely that the degradation of the 
hormone receptor complex is due solely to protease digestion though 
Schoenberg & Clark (1980) have reported loss of oestrogen-binding 
sites due to nuclease action.
3
The binding of ( H) - oestradiol to nuclear oestrogen receptor (pre­
filled with unlabelled oestradiol) at low temperature (*on-rate*) also 
indicates that there is a significant exchange rate at 4°c (Fig. 3.6). 
However, the *on-rate*, or association rate, appears much more rapid 
than the corresponding *o<ff-rate*. This is particularly marked for 
the binding of oestradiol to receptor from the crude nuclear pellet. 
Hansen ef ^1 (1976) reported that the association rate constant of the 
progesterone receptor varied more with temperature than did the 
dissociation constant. Weichman & Notides (1977) reported that the 
association constant, unlike dissociation constant, of oestrogen receptor 
from calf uterus was unchanged by salt concentration or by sodium 
thiocyanate. These two reports indicate that changes in one of the 
binding constants is not necessarily reflected in its opposite rate 
constant, though the significance of this is unclear. However, the
much slower •on-rate* noted, with purified nuclei might indicate that 
the early rapid binding could be due to damaged nuclei or to a small 
portion of contaminating cytoplasmic or membrane bound receptor 
(Szego & Pietras, 1977; 1979). The difference is most likely 
ascribed to damaged nuclei since the levels of membrane or cytoplasmic 
contamination of the crude nuclear pellet appear to be fairly small.
The final receptor concentration of receptor per j i g  o f  DNA was the 
same for both the * crude* and *purified* nuclear preparations.
The initial off-rate from *purified* and * crude* nuclear pellets also 
shows small differences (Fig. 3.5) but these changes seem inconsistent. 
However the overall extent of exchange of 4 ° c and 20^c is the same in 
both crude and purified nuclei suggesting that these differences may 
not be significant.
4.2 SALT EXTRACTION
In agreement with the observations of Katzenellenbogen e^ ^  (1980) 
and King (1982) 0.6M KCl was found to solubilise only about 50% of 
the human nuclear oestrogen receptor. This reinforces the original 
criticisms of salt extraction of nuclear receptor (Clark & Peck, 1976), 
that the salt resistant fraction is the fraction which is attached to 
the high affinity specific acceptor, or gene regulator sites.
Although widely accepted,this has been criticised by a number of groups 
(Muller e_t 1977; Traish ad, 1977; Borgna & Ladrech, 1982).
Recent reports by Lippman*s group (Stobl ei^  1982; Kasid et 1982)
have linked 'processed* nuclear receptors with salt resistant nuclear 
receptors by demonstrating that the processed receptor exhibits a
slower exchange rate and an increased resistance to salt extraction.
In these experiments the human tissue would already have been exposed 
to oestrogens and therefore the nuclear receptor would be present 
in the processed form. However from Table 3.2 it can be calculated 
that roughly 5000 salt resistant sites are present in each nucleus.
Such a calculation is necessarily inaccurate but the number of sites 
involved appears to be in excess of the number of sites of genetic 
regulation even allowing for co-operative effects of nuclear receptors 
and multiple interaction sites (Leake,1981 a; Palmiter ^  ad, 1981),
The method which is used to distinguish between nuclear receptors 
controlling gene expression (salt resistant nuclear receptors) and 
the bulk of nuclear receptors (salt soluble receptors) which have no 
effect on gene regulation, was arrived at empirically, after studies 
on the oestrogen receptor in rat uterus, (Clark & Peck, 1976). It 
may be that the greater proportion of salt resistant nuclear receptor 
in human tissue compared to rat uterus reflects a species difference 
and indicates that oestrogen receptor in human tissue is bound to 
chromatin with a higher affinity.
One of the principal reasons for the variation in the published 
estimates is the different rate of exchange in chromatin bound and 
salt extracted nuclear oestrogen receptor (Fig. 3.3 and Fig, 3.7).
However the various differences in the off-rate of oestradiol from 
salt extracted nuclear receptor reported in the literature may, at 
least in part, be due to interlaboratory differences in salt concentration 
(Weichman & Notides, 1977; Lukola et ad, 1981) although the
dissociation constant of oestrogen from its receptor has also been
reported as sensitive to triton (Pavlik & Rutledge, 1980; De Boer & 
Notides, 1981) and high concentrations of oestradiol (Borgna & Ladrech, 
1982). In particular De Boer & Notides (1981) have concluded that 
the dissociation rate reflects the conformational state of the 
oestrogen receptor. The rate of exchange of oestradiol from HAP 
bound receptor is lower at 20^c (Fig. 3.7) than that from chromatin- 
bound receptor suggesting that the extracted nuclear oestrogen 
receptor complex is generally more stable than when still bound to 
chromatin. This contrasts with a report by Sala-Trepat & Reti (1974) 
that nuclear receptor complex from calf uterus was less stable at 22^c 
after salt extraction. However both Sala-Trepat & Reti (1974) and 
De Boer & Notides (1981) reported that binding salt-solubilised 
nuclear receptor to HAP increased the stability of the hormone-receptor 
complex.
Although most of the differences in the r^orted extent of exchange 
at low temperature can be attributed to the different methods used, 
two papers (Blankenstein et al, 1979; Pavlik & Rutledge, 1980) which 
reported a high rate of exchange at 4^c from HAP bound nuclear receptor 
remain unexplained. These two papers had measured the exchange rate 
in 0.6m KCl, in contrast to the usual HAP method at low ionic strength, 
suggesting that ionic strength of the medium could affect the rate of 
exchange.
As reported by Lukola et al, (1981) increasing the ionic strength 
was found to increase the rate of exchange of steroid from HAP-bound 
nuclear receptor at 4°c. Fig. 3.7 and 3,8 indicate that increasing 
the ionic strength can cause almost as large a change in the exchange
rate as increasing the temperature. The corollary to this result 
is that salt extraction of nuclear receptor, usually for 1 hour at 
4^c in 0.6M KCl, would cause an apparent increase in the amount of 
unoccupied nuclear receptor which is detected. Such stripping of 
endogenously filled nuclear receptor, confirmed by the demonstration 
that the lost radiolabelled oestradiol can be removed as unbound 
steroid (Fig. 3.8 legend), suggests that the HA.P method of measuring 
nuclear receptor may give rise to an underestimate of filled nuclear 
receptor content and will necessarily lead to an ovarestimation of 
the proportion of unoccupied nuclear sites.
The use of different extraction methods (different salt concentrations 
and incubation times) may explain why there has been a wide variation 
9 - 75% (Horwitz & McGuire, 1978b; Geier a^, 1980) in published 
estimates of the proportion of nuclear oestrogen receptors which are 
unoccupied. Unoccupied nuclear receptors were originally proposed 
as the reason for oestrogen receptor positive tumours failing to 
respond to endocrine therapy (Panko & McLeod, 1978; Thor sen & Stoa,
1979). The more recent reports (Carlson & Gorski, 1980; Levy et al, 
1980; Thrower et al^ , 1981) which demonstrate unoccupied nuclear 
receptors in most oestrogen target tissues suggest that they are a 
general phenomenon resulting from oestrogen action. However it seems 
unlikely that the actual function of unoccupied nuclear receptors will
be elucidated until the amount of this class of nuclear receptors can
be accurately measured. Therefore, in future, more attention should
be given to the effects of salt and temperature on the levels of
unoccupied nuclear receptors detected.
Fig. 3,9 indicates that the salt resistant nuclear receptor has the 
same exchange rate, at both 4*^ c and 20^c, as the total receptor 
content of untreated nuclei in the crude nuclear pellets. This 
shows that the rate of exchange cannot be used to differentiate between 
salt resistant and salt extractable nuclear receptor.
There is now increasing evidence that measurement of nuclear oestrogen 
receptor content in breast tumours, whether measured in intact nuclei 
or in a salt extract can improve the value of receptor as a clinical 
index of both potential response of advanced breast cancer to 
endocrine therapy and of prognosis of primary disease (Leake, 1981b). 
It is therefore important that the estimates of both filled and empty 
nuclear receptor should be as reliable as possible.
Therefore, in conclusion, a number of factors can affect the stability 
of the human oestrogen receptor. These factors, and the differences 
between the human and rat forms of the oestrogen receptor, should be 
considered when receptor levels are measured.
PART II
Growth o f breast tumour cells in vitro
5. INTRODUCTION
5.1 PRIMARY CULTURE OF MAMMARY TUMOUR CELLS
It has been recognised for many years (Lasfargue & Ozzello, 1958) that 
primary culture of epithelial cells from human mammary tissue would 
be valuable, for example there exists no reliable guide for the 
selection of the optimal therapeutic regime, or combination of regimes, 
for the treatment of individual patients. A method for culturing 
mammary tumour biopsies could provide both a system for individually 
testing the efficacy of potential treatments and be of great value in 
the screening of new drugs. A specific objective in developing mammary 
tumour cell culture would be to provide a method to examine oestrogen 
induced stimulation of epithelial growth and the mechanism of its 
inhibition by tamoxifen. This should both identify patients suitable 
for tamoxifen therapy and extend our understanding of the mechanism of 
action of anti-oestrogens in human tissue. Physiological defects 
which are not apparent in a receptor assay may become evident under 
culture conditions (Burstein et 1971; Wellings & Jentoff, 1972;
Aspergen al, 1975). There are certain physiological defects which 
would be particularly suitable for study using tissue culture. These 
include 1) the presence of oestrogen receptors in apparently hormone- 
independent tumours, 2) clonal variation within a breast tumour, i.e. 
tumours which contain a mixed population of hormone dependent and 
independent cells and 3) the possibility of transition of an individual 
cell or group of cells from hormone dependence* to independence.
Primary culture of breast tumour biopsies could provide an alternative
in vitro model of breast cancer. At present there are three systems 
available for the study of hormonal involvement in mammary tumours -
1) The DMBA induced rat mammary tumours, which can be hormone dependent 
or independent (even within the same rat) (Huggins e;t 1959), though
these tumours are frequently more sensitive to peptide hormones such
as insulin (Cohen & Hilf, 1974) and prolactin (Asselin & Labrie, 1978),
2) Small pieces of breast tumour biopsies can be maintained for short 
periods in organ culture but the validity of these experiments has been 
questioned (see Section 5.4.2) because of cell damage both during 
preparation and due to anoxia in culture. The cells within each 
explant in organ culture remain viable for only a few days,
3) Cell lines derived from pleural effusions, the most studied of 
which is MCF-7 (Soule et 1973). This cell line has been shown
to contain receptors for androgens, oestrogens, glucocorticoids and 
progesterone, and growth can be stimulated by oestrogen (Horwitz al,
1975) (for problems with MCF-7 see Section 5.4).
A method for the primary culture of solid tumours would provide a useful
model for studying both the mechanism of hormone action in tumours and 
the effects of anti-tumour drugs. In the past, it has proved very 
difficult to culture epithelial cells from solid tumours (Whitescarver, 
1974) though it has been possible to culture normal breast epithelium 
(Ebner, 1961; Stampfer et ad, 1980). The main reasons given for the 
lack of success are the low yield of epithelial cells and their slow 
growth rate. The yield of epithelial cells is low due to the large 
proportion of dead cells in a solid tumour as a result of previous 
therapy, necrosis or calcification (Buehring & Williams, 1976). Breast
fibroblasts replicate at a much higher rate than epithelial cells (Owens
et al, 1976). They grow over epithelial colonies (Stoker et 1978)
and coat them in collagen (Lasfargue, 1973) limiting access to nutrients 
and preventing dispersal of epithelial cells during sub-culturing, 
which effectively prevents epithelial growth.
Another reason, proposed to account for the low yield, is damage to 
the very fragile epithelial cells during tissue disaggregation (Wiepjes 
& Prop, 1970). The method used to establish the first cell lines 
from solid tumours (Lasfargue & Ozzello, 1958) involved a dissection 
technique in which epithelial cells were spilled from the tissue by 
careful slicing. More receitly enzymatic disaggregation using 
collagenase has become the preferred method.(Hamburger et ad, 1982),
Unlike trypsin, (Lasfargue & Moore, 1971) collagenase digests stroma, 
causes little epithelial cell damage and is not inactivated by serum, 
calcium or magnesium (Ceriani ad, 1978). Epithelial cells can
endure long exposure to collagenase and still recover (Freshney, 1972).
Only a small percentage of the attempts to establish permanent cell 
lines from solid human breast tumour biopsies have succeeded. These 
include BT-20 (Lasfargue & Ozzello, 1958) Al-Ab (Reed & Grey, 1962)
G-11 and HBT -39 (Plata ^  1973) SW-613 (Liebovitz, 1973) and B-0
(Nissen et a3^ , 1980). The very low level of success in establishing 
cell lines suggests that these cell lines are due to the mutation of a 
single cell, or that the original tumours were abnormal in some way.
Such cell lines have not been widely utilized, compared with MCF-7,
and this must imply doubts about their validity as a model of breast cancer,
More recently there have been r^orts of successful maintenance of primary
cultures of breast tumour cells for short periods (Buehring & Williams, 
1976; Kirkland et al, 1979). This has allowed a comparison between 
growth of tumour cells and normal breast epithelium, and the effects 
of hormones and growth factors to be studied (Kievjar - Anderson & 
Buehring, 1980; Yang ad, 1980a; Smith ^  1981a). It is much
more reasonable to expect short-term primary cultured cells to reflect 
those of the parent tumour than it is for established cell lines to 
do so.
5.2 SELECTION OF EPITHELIAL CELLS
The most successful method cf selecting for epithelial cells has been 
to cover the culture vessel to prevent stromal attachment. This was 
first achieved by coating the surface of the flask with rat tail collagen 
(Ehrmann & Grey, 1956). This method is still in use (Yang _et ad, 1980b) 
but because rat tail collagen gels have a tendency to tear (allowing 
fibroblast growth) the use of either floating collagen gels (Katiyer 
et al, 1978) or agar (Asano & Mandel, 1981) has become more popular.
A variation of this melhod is to grow a monolayer of appropriate cells 
then arrest division by irradiation or mitomycin C treatment.
This 'feeder layer* aids growth by preventing stromal attachment 
(Rheinwald & Green, 1975 a; b) amd possibly by conditioning the medium 
(Armstrong & Rosenau, 1978). The fibroblast line of Swiss 3T3 cells 
has been successful and breast foam cells (non-dividing epithelial cells 
from human milk) (Taylor-Papadimitrou ^  ad, 1977b) have also been used 
as a feeder layer.
other meüiocis have relied on the more stringent growth requirements 
of fibroblasts. The omission of foetal calf serum (Puck ejt ad, 1958) 
or the addition of the D forms of certain essential amino acids, e.g. 
valine (Gilbert & Migeon, 1975) prevents or retards the growth of 
fibroblasts while permitting epithelial cells to grow.
Fibroblast attachment can be selectively inhibited by controlled 
exposure to proteases (Owens, 1974; Matsumara ^  1975). Separation
of epithelial cells from stromal cells can be adhieved by using Ficoll 
(Sykes e]^  al, 1970) or Percoll (pertoft et ad, 1977) density gradients. 
Cis-hydroxy proline has been added to cultures to prevent collagen 
formation and so inhibit smothering of epithelial cells (Kao & Prockop, 
1977; Liotta et al, 1978). Edwards et ^  (1980c)have isolated a 
monoclonal antibody to fibroblasts and regular treatment with the antibody 
plus complement.consistently killed fibroblasts, eventually leaving 
sheets of epithelial cells.
5.3 STIMULATION OF EPITHELIAL CELL GROWTH
5.3.1. GROWTH FACTORS
The mitogen epidermal growth factor (EGF) was first discovered in the 
mouse submaxillary gland (Cohen, 1962; Cohen & Elliot, 1963). It was 
first reported to specifically stimulate epithelial cells (Turkington,
1969) but the glycoprotein receptor for EGF has also been found in 
fibroblasts (Hollenberg & Cuatercases, 1973; Cohen ejb 1975) where
EGF stimulates cell proliferation and reduces the serum requirement 
(Armelin, 1973; Carpenter & Cohen, 1979). EGF increases colony formation 
and growth of breast epithelial cells on feeder layers (Rheinweld &
Green, 1977; Taylor-Papadimitrou et al, 1977a) and normal substrate 
(Stampfer ^  1980; Yang £t al, 1980a).
Yang _et ^ , (1980c) also reported the agents that increased cellular 
cAMP, in particular cholera toxin, favoured mammary epithelial 
proliferation though the response of tumour cells was more inconsistent 
than normal cells. Smith elb ad (1981a) have routinely used cholera 
toxin to maximise the growth of both malignant and nonmalignant breast 
epithelia. The inconsistent response of tumour cells may be due to 
the variable ijQ situ elevation of cAMP levels in malignant breast 
tissue (Elliot e^ a^, 1981).
Conditioned media (spent medium from other cell lines) from human 
epithelial or myoepithelial cell lines have been found to increase the 
growth of both normal and malignant breast cells in culture (Stampfer 
e;t aj^ , 1980; Smith et 1981a). This suggests that some factor or
factors are secreted by growing cells which are required for the growth 
of breast epithelial cells but which are not present in suitable amounts 
in normal serum of calf or human origin. The cell lines used to supply 
the conditioned media are usually human epithelial cells of foetal or 
embryonic origin (Armstrong & Rosenau, 1978; Stampfer e^ 1980)
suggesting that the factor(s) may only be able to cross-react between 
certain compatible cell types.
Though serum is apparently not essential for epithelial cell culture 
(Puck et aJL, 1958) it does stimulate growth. Human serum has a greater 
effect than bovine serum (Foley & Aftanomus, 1965). Page (1982)
have recently reported a factor in human serum which is required for a
response to oestrogen in MCF-7 cells.
Exposure to carcinogenic phorbol esters has aided in the establishment 
of primary cultures by stimulating the growth rate (Steele et al, 1978). 
Crude extracts of human urine, kidney or brain have been found to 
stimulate growth of normal breast epithelial cells (Yang et. 1980a).
The active ingredient(s) in these extracts has not been identified 
but might simply be human EGF known to be present in human urine 
(Carpenter & Cohen, 1979),
5.3.2 HORMONES
The growth and development of breast cells depends on the stimulation 
and interaction of a number of hormones (Topper, 1970; Young e^ 1978).
Much of the information regarding the action of hormones has been provided 
by studies of explants of immature mouse mammary gland iu vitro.
Cortisol (Mills & Topper, 1970) and insulin are required for the 
differentiation of mammary epithelial secretory cells. Prolactin 
stimulates milk secretion including the synthesis of milk proteins.
For example, the synthesis of casein and of o<lactalbunin can be induced 
in mammary gland tissue previously incubated with cortisol and insulin 
in vitro and then exposed to prolactin (Turkington et 1967;
Turkington, 1970),
During pregnancy prolactin acts synergistically with insulin to promote 
development of the mammary gland by increasing the synthesis of protein 
kinases. Insulin has been shown to stimulate the growth and development 
of the mammary gland (Topper, 1970). Oestrogen causes the development
of the alveolar system in the mammary gland. Progesterone inhibits 
the formation of the milk proteins casein and cxlactalbumin while allowing 
growth and differentiation of mammary epithelial cells. With the 
expulsion of the placenta at parturition and the decreased progesterone 
levels, the synthesis of casein and «xlactalbumin increase rapidly 
(Conn & Cowie, 1980). There is considerable species differences in 
the hormonal control of mammary gland development (Forsyth & Hayden, 1977) 
with the human breast being the most oestrogen sensitive of all primates 
(Short & Drifie, 1977).
5.4 HUMAN MAMMARY CARCINOMA IN CULTURE
5.4.1. CELL LINES FROM SOLID TUMOURS
No routine method has been established for the formation of cell lines 
from solid breast tumour biopsies. Only a small number (see Section 5.1) 
of the attempts to culture solid tumours have succeeded in the formation 
of a cell-line (Lasfargue & Ozzello, 1958; Reed & Grey, 1962; Liebovitz, 
1973; Plata et 1973) while Cailleau et (1978)_^ Owen'et al. (1976),
Trempe (1976), and Whitescarver (1974) have'all reported no success 
from a large nui±> er of attempts. These cell lines are not regarded as 
good ijn vitro models of breast cancer and have not become as popular 
a research tool as MCF-7 cells for several reasons: 1) Despite numerous
attempts, only a small number of cell lines have beoi established and 
this has led to doubts on whsther the cell lines are representative of 
the tumour from which they were derived or of breast tumours in general
2) poor growth rate of these cell lines (relative to MCF-7) and 3) many 
of the cell lines contain no steroid receptors while others show little 
response (in terms of increased cell growth) to steroids.
5.4.2 ORGAN CULTURE OF HUMAN BREAST TUMOURS
Most attempts at organ culture of human breast cancer appear to have 
been unsuccessful. Most authors were unable to maintain viable tumour 
tissue for even a few days (Wellings & Jentoff, 1972; Lagois, 1974) 
although one group have reported routinely culturing biopsies for up 
to 14 days. Some authors have attempted a tissue survival test 
(Chayen et 1970; Hobbs ^  1973) and reported that hormone
supplementation could improve the survival of some tumours but not 
others. These methods have been strongly criticised (Heuson & Tagnon,
1973) and testing the action of hormones on dying tissue seems meaningless 
Experiments attempting to identify hormone-dependent [MBA induced rat 
mammary tumours by measuring hormone sensitivity in organ culture 
concluded that results varied with length of incubation time (Aspegren 
et al, 1975) and that a hormone receptor assay on a fresh tumour section 
was more accurate (Kinoshita, 1980).
5.4.3. CELL LINES FROM PLEURAL EFFUSIONS
There has been much more success in establishing cell lines from pleural 
effusions (Illiger ^t al_, 1975) probably because of the very low stromal 
content (Soule e;^  ad, 1973; Cailleau e^ al, 1978). The most studied 
cell line of this type is MCF-7 which was derived from the pleural 
effusion of a patient with an oestrogen receptor positive breast tumour.
It has been rigorously characterized with respect to morphology (Russo 
et al, 1976 ; 1977) chromosomal studies (Soule ^  1973) and
secretion products (Rose & McGrath, 1975; Lippraan e;t 1976). MCF-7
cells respond to hormonal stimulation (Lippman & Bolan, 1975; Lippman
et al, 1976) and contain receptors for oestrogen (Brooks e;t a]^ , 1973) 
androgen, glucocorticoids, progestins (Horwitz ^  1975), insulin
(Osborne ei^  ad, 1978), prolactin (Shiu, 1979) and vitamin (Eisman 
et al, 1980). The injection of MCF-7 cells into nude or athymic mice 
results consistently in the rapid formation of métastasés, frequently 
with structural morphology similar to the original tumour.
The cell line has been widely used to study oestrogen receptors (Edwards 
et al, 1980a; Geier ^  1981), mechanism of action of hormone/receptor
complex in relation to chromatin (Horwitz & IVfcGuire, 1978 a & b; Sheridan 
et al, 197 9) oestrogen stimulation of DNA. polymerase (Edwards ^  al, 
1980b) interaction of androgens with oestrogen metabolism (Zava &
McGuire, 1978 a ; b), effects of tamoxifen (Allegra & Lippman, 1978) 
and has been proposed as an fn vitro model for studying oestrogen 
responsive breast cancer (Lippman e;t ad, 1976).
Cells from a pleural effusion may derive from a highly selected section 
of the breast tumour and, therefore, may not be representative of the 
tumour as a whole. This, perhaps, reduces their potential. Problems 
have arisen because MCF-7 lines held in different laboratories no longer 
appear identical and there have been various 'sub-clones' reported 
(Nawata et 1981 a ; b). There have been reports of a decrease in
(Briand & Rose, 1981) or loss of (Nawata ad, 1981b; Page elb ad, 1982) 
response to oestrogen, loss of certain hormone receptors, dependence of 
oestrogen stimulation on a serum factor(s) (Page et 1982) and
translocation of the oestrogen receptor to the nucleus followed by 
stimulation of cell growth after treatment with 17o< oestradiol, (Edwards 
& McGuire, 1980). Page et ad (1982) found a change in the number of
chromosomes in their MCF-7 line from the original 88 reported by Soule 
ei^  ad (1973) (compared with 46 for a normal cell).
5.4.4. PRIMARY CULTURE OF BREAST BIOPSIES
Recently a limited amount of success has been achieved in maintaining 
breast tumour cells in culture for short periods of time (Kirkland e^ ad, 
1979; Klevjer - Anderson & Buehring, 1980; Smith et 1981a). Most
of these reports have concentrated on attempting to maximise 1) the 
rate of growth 2) the survival time and 3) the ability to survive and 
replate after passaging (subculturing). All three of these functions 
are normally poor in comparison with other types of primary cultures. 
These methods rely on utilizing a feeder layer or adapted substrate 
and/or medium to prevent stromal growth and require rich media (including 
high levels of serum) and combinations of hormones, growth factors and 
other mitogens.
Although most reports agree that insulin causes increased growth 
(Gaffney & Pigott, 1978; Stampfer ad, 1980; Yang e;^  ad, 1980a) they 
disagree on the extent of stimulation caused by insulin. Growth 
factors, such as EGF, and mitogens, such as cholera toxin, while 
increasing the growth rate of normal breast epithelium, were found to 
have a more variable effect on breast tumour cells (Kirkland et ad,1979; 
Yang ^  a^, 1980a). Opinions vary over the effect of steroid hormones. 
Oestrogens have been reported as having no effect (Kirkland ^  1979),
a varied effect (Barker & Richmond, 1971), or occasional stimulation 
(i.e. 2 tumours out of 12) while the glucocorticoids have been more 
consistently reported as causing an increase in growth rate (Gaffney &
Pigott, 1978; Kirkland e;t ad, 1979; Stampfer ^t a^, 1980),
Although most studies have been concentrated on improving the growth 
conditions, a few groups have begun to use the technique of primary 
culture of breast cells, to study surface antigens of normal and 
abnormal breast tissue (Peterson ;^t al, 1978; Sasaki e;t al, 1981) 
adriamycin sensitivity (Smith et ad, 1981c) and the relationship of 
concanavalin A reactivity with early disease recurrence (Furmanski 
et al, 1981).
Cell culture has been criticised (Pasteel et al, 1976) because only 
one cell type is studied, in isolation, and there is no collagen matrix 
with which the cells may interact. But primary culture has several 
advantages when compared with either organ culture or use of established 
cell lines. The cells in primary culture do not remain in culture long 
so that mutation and adaptation to culture conditions can be minimised. 
They respire and divide 'normally* and a large number of biopsies can 
be studied so that the heterogeneity of human tumours can be investigated, 
In the future, primary culture of breast cells may be useful in raising 
and testing monoclonal antibodies against breast tumour antigens.
5.5 IDENTIFICATION OF CELL TYPE
Once a cell line is established it is important that it is fully 
characterised. This involves demonstrating the presence of certain 
specific markers which are indicative of the cell type and origin.
5.5.1. HUMAN MAMMARY MARKERS
Specific products of the normal mammary gland can be used as markers. 
Products which have been used as markers include cMactalbumin (Rose & 
McGrath, 1975; Woods al^ , 1979) which is often retained in tumours, 
casein (Hurilmann 1976; Franchimont al, 1977) which is
occasionally retained and milk fat globule proteins (Ceriani ^  al, 
1977; Sasaki et 1981).
Other possible breast markers are gross cystic disease protein 
(Haagensen et al, 1978) believed to be an epithelial cell secretory 
product; lactoferrin (Hurilmann £t ad, 1976) and non-histone nuclear 
antigen (Shiu ^  1977 ) .
Markers which indicate mature breast cells to be both human and 
malignant include Carcinoembryonic antigen (CEA) (Cantwell ^  al, 
1980; Walker, 1980) Human chorionic gonadotropin (hCG) (Horne et ad,
1976) Pregnancy associatedGlycoprotein (Stimson e^ ad, 1977) and 
Gamma foetal proteins (Edynak, 1972). All of these have beai reported 
as present in human breast cancers vivo.
Sasaki e^ ^  (1981) have studied human mammary epithelial antigens 
which are expressed in culture. They found four major protein 
components which are expressed in high levels in primary culture of 
normal breast and in lower levels in breast cell lines from pleural 
effusions and breast tumour cells in primary cultures (Peterson e;t al, 
1978).
5.5.2 MARKERS OF MALIGNANCY
There has been no correlation found between structural differentiation 
and malignancy except that tumour cells display a polyploidy which 
normal breast cells rarely do (Macpherson, 1970). Periodic chromosomal 
examinations (Nelson - Rees et ad, 1974) are also important when using 
established cell lines because in the past several lines have been 
found to consist totally or largely of HeLa cells (Buehring & Hackett,
1974).
Injection of cells into thymectomized (or nude) mice (Fogh & Giovanella, 
1978) can show that the cells are malignant, but the absence of a 
tumour does not indicate that the cells are not malignant (Marshall 
et al, 1977). Tumours can be raised in nude mice from transplanted 
solid tumours (Giovanella e^ ad, 1978) or from cells cultured from 
solid tumours (Giovanella et al, 1974) or pleural effusions (Shafie,
1980). The rate of success from all solid tumours is about 50%, with 
breast tumours being the most unsuccessful (Shiraosata ^  ad, 1976; 
Giovanella et 1978). The success rate for established cell lines
is much higher, depending largely on the number of cells innoculated 
(Giovanella 1974; Shafie, 1980). The tumours raised in nude
mice usually closely resemble the morphology of the original tumour 
(Shimosata et 1976) and growth of MCF-7 cells in nude mice is
truly oestrogen dependent, whereas in culture they will grow in the 
absence of oestrogen (Shafie, 1980; Shafie et al, 1981).
The capacity to grow in soft agar has been used to demonstrate malignancy 
(Das al, 1974). Tanigawa et ^  (1982) have recently reported
growing breast tumour cells in soft agar although caution must be 
exercised since, in one rqport, colonies formed in soft agar from 
breast tumours have been subsequently identified as T lymphocytes 
(Asano & Mandel, 1981). The levels of cathepsin B, which digests 
collagen and proteoglycan, are elevated in malignant cells (Poule ^t al, 
1978). However this would not be the ideal test for cells in culture 
since 1) it relies on detecting a relative increase in the level of 
enzyme, 2) changes may have occurred because the cells are in culture 
and 3 ) the cell population may be mixed.
Recently plasminogen activator has become favoured as a specific 
marker of malignancy. The major form has been characterised as a 
serine protease of 39,000 molecular weight with arginine specificity 
which preferentially cleaves one fraction of plasminogen (Unkles _et al, 
1973; 1974). High levels of plasminogen activator have been reported 
as one of the first detectable changes resulting after carcinogen administ­
ration and tumour formation in rats (Hince & Roscoe, 1978), The release 
of plasminogen activator is inhibited by interferon (Schorder e^ ad, 1978) 
Release of plasminogen activator can be demonstrated by a technique 
measuring the digestion of a fibrin overlay (Jones ^  1975) or by
measuring release of fluorescent tagged (Whur et 1980), or
radioactively labelled, fibrin by plasminogen activator in spent medium.
Plasminogen activator has been found in breast and cervical tumours 
(Pearlstein 1976; Tucker ejt ad, 1978) but not in normal cells of
the same origin. It is also present in a range of human tumour cell
lines (Nagy et 1977), However doubts have been raised by studies
of rat liver where no correlation has been found between its production
and malignancy (San ©;t ad, 1977;. Howett ^  1978). More recently
Yang et ^  (1980c) have shown that plasminogen activator is released 
from both normal and malignant mammary cells in culture. However 
Wilson ^  ^  (1980) have shown that different molecular weight forms 
of plasminogen activator are produced by normal and malignant cells in 
culture. The need to determine molecular weight would increase the 
complexity of the assay but this would be justified if it was confirmed 
as a reliable marker of malignancy. The assay of plasminogen activator 
would also prove very useful if the release of this and other proteases 
could be related to the invasive potential of the breast tumour.
5.5.3 MARKERS OF EPITHELIAL CELLS
Epithelial cells can easily be distinguished in culture by growth 
pattern and morphological characteristics (Bassin ^  1972) such
as the 'paving-like’ arrangement of cells or the formation of domes, 
(Young ^t ^ 1 , 1978; Smith e_t ad, 1981b). The electron microscope is 
the most routinely used method to define the epithelial nature of 
cultures by identifying desmosomal junctions, tonofilaments, microvilli 
and large irregular nuclei (Owens et 1976; Cailleau ^  ad, 1978).
The presence of tonofilaments can also be demonstrated using monoclonal 
antibodies raised recently by Lane (1982),
The mammary epithelial antigens (Section 5,5.1) used by Peterson ^  al. 
(1978) are present in normal breast epithelial cells situ in high 
levels but in lower amounts in cultured normal or malignant cells.
They are also found in trace amounts in breast fibroblasts. The ability 
of epithelial cells to coat collagen gels and protect them from
collagenase has been used to identify them (Kanoza e^ t al, 1978) but 
this requires a large number of, or rapidly growing, epithelial cells 
and is, therefore, unlikely to be of use as a marker in primary culture 
of breast cells.
5.6 OESTROGEN RECEPTOR ASSAY IN TISSUE CULTURE
As yet there is no simple and accurate method for detecting hormone 
receptor in a small number of cells. Present receptor assays, such 
as those using dextran coated charcoal, require a minimum of 100 mg of 
cells per assay and so are of value only for cells with rapid growth 
rates, similar to MCF-7*s, where a large number of cells can be quickly, 
generated.
A number of groups have published autoradio graph i c methods for use in 
tissue culture (Arnold, 1981; Sheridan £t ad, 1981; Stumpf et 1981)
though it may prove difficult to distinguish between specific and non­
specific binding of labelled steroid.
Recently there have been a large number of reports of histochemical 
methods for detecting oestrogen binding (Pertschuk ^  ad, 1978; Walker 
et al, 1980; Nenci e^ al, 1981). As yet none of the methods have 
come close to fulfilling all the requirements for a histochemical 
receptor assay to be considered valid (chamness et ad, 1980). The main 
drawback is in the concentration of oestrogen analogue needed. The 
lowest effective concentration is 10 M which is 100 - 1000 fold in 
excess of the physiological level. This suggests that the type II 
binding sites (Markaverich e^ ad, 1980) are being detected rather than
the functional cellular oestrogen receptor. If it can be shown that 
type II occur only if type I is present then the method may be of 
value for clinical use in rapidly predicting tumours which will respond 
to oestrogen. However the histochemical methods must become more 
reliable and quantitative before they can be used as a research tool.
A natural oestrogen coumestrol may be of use in detecting the oestrogen • 
receptor in culture since it absorbs at 340nm and fluoresces at 410 nm.
It can only be used in cell culture because in tissue, elastase and 
collagen fluoresce strongly at 410 nm (Pertschuk et al, 1980),
The development of monoclonal antibodies to the oestrogen receptor 
(Greene et 1977; Greene _et 1979; Coffer ^  al^ , 1980) may provide
an alternative method. But problems still remain with detecting 
receptor after the cells or tissues have been fixed. Furthermore, 
the antigenic sites do not seem to be limited exclusively to the 
oestrogen receptor.
The use of antibodies against the oestrogen molecule itself, has been 
proposed as a method for detecting tissue which contains oestrogen 
receptor (Nenci al. 1976 a ; b). Unfortunately it would seem 
extremely unlikely that antibodies would be able to bind oestrogen 
while it was bound to the oestrogen receptor. Furthermore, oestrogen, 
particularly at the levels used, will almost certainly be retained 
within membranes.
It may prove possible to adapt the technique for measurement of oestrogen 
receptor by isoelectric focusing to detect receptor in small volume
extracts from tissue culture. This technique has been found to 
correlate well with the dextran coated charcoal assay (Lloyd et al, 
1982).
5.7 OBJECTIVES
The purpose of this work is to develop a method for the routine growth 
in culture of cells from human breast tumour biopsies. This will 
involve determining the conditions which maximise tumour cell growth 
and survival. Cells grown from biopsies will be characterised as 
fully as possible to demonstrate their origin, cell type and malignancy. 
An attempt will be made to evaluate the possible use of primary culture 
to detect 1) hormone responsive tumours 2) to act as an vitro model 
of breast cancer and 3) to test anti-tumour drugs.
6. CELL CULTURE MATERIALS AND METHODS
6.1 MATERIALS
6.1.1 MEDIA
Ham's F 10 (lOx) (Ham, 1963) was obtained from Flow Laboratories, 
Irvine, Scotland. A full list of ingredients is provided in the 
Flow laboratories catalogue page 51.
6.1.2 ANTIBIOTICS were obtained from the following
"Crystapen" benzyIpenici1lin (sodium) BP 
Streptomycin sulphate BP 
"Kanasyn" kanamycin sulphate BPC 
Mitomycin C 
Gentamicin
Fungizone (amphotericin ^  )
Glaxo
Glaxo
Sigma, London
Sigma, London
Flow Laboratories, Irvine, 
Sco tland
Gibco Bio-Cult, Paisley, 
Scotland
6.1.3 FINE CHEMICALS were obtained as follows
Foetal Calf Serum
Glutamine (200mM)
N-2-hydroxypiperazine-N*-2-ethane 
sulphonic acid (HEPES) IM
Non-essential amino acids
Sodium Bicarbonate (7.5%)
Gibco Bio-Cult, Paisley,
Scotland & Flow Laboratories, 
Irvine, Scotland
Gibco Bio-Cult, Paisley,
Scot land
Gibco Bio-Cult, Paisley,
Scot land
Gibco Bio-Cult, Paisley, 
Scotland
Flow Laboratories, Irvine,
Scot land
Hanks balanced salt solution (BSS) 
Giemsa stain
Solvent methanol (Microscopical grade 
reagent)
Depex
Glutaraldehyde 25%
Osmium tetroxide 
Propylene oxide 
Araldite mixture 
Vitrogen 100 collagen
Flow Laboratories, Irvine, 
Scotland
BDH, Poole, Dorset
BDH, Poole, Dorset
Hopkin and Williams, Essex
lAAB Laboratories, Reading, 
Berkshire
TAAB Laboratories, Reading, 
Berkshire
EM Scope Laboratories, 
Ashford, Kent
EM Scope Laboratories, 
Ashford, Kent
Flow Laboratories, Irvine, 
Sco tland
All other reagents used were BDH "Analar" grade.
6.1.4 HORMONES AND GROWTH FACTORS were obtained as follows
Oestradiol -17^
Insulin
Cortisol
Prolactin (ovine) 
Epidermal Growth factor
Cholera toxin
Sigma, London 
Sigma, London 
Sigma, London 
Sigma, London
Collaborative Research Inc., 
Mass., U.S.A.
Sigma, London
6.1.5 ENZYMES were obtained as follows
Collagenase type 1 
Trypsin (2.5% solution) 
Protease, neutral (Dispase II)
Si gma, Lo ndon
Flow Laboratories, Irvine
Boehringer Corporation 
(London) Ltd.
6,1.6 PHOTOGRAPHY
D 19 Developer
Kodak Electron microscopy film 4489
ARID fine grain autoradiographic 
stripping film
Ilford Panatomic X
Arafix
Kodak Ltd., England 
Kodak Ltd., England 
Kodak Ltd,, England
II ford Ltd,, England
May & Baker, Dagenham, Kent
6.1.7 CELL LINES
3T3 : Swiss mouse fibroblast line (Todaro & Green, 1963)
6.1.8 RADIOCHEMICALS
(methyl-^H) thymidine (25 Ci mmol ^) 
(6-7-^H) 17^ oestradiol (54 Ci mmol ^) 
(1,2,6,7 -^H) cortisol (30 Ci mmol ^ ) 
were supplied by Amershaim International
6.1.9 m i s c e l l a ne o u s
> Tissue culture flasks were obtained from Falcon, Division of Becton,
Dickinson & Co., Oxnard, California, U.S.A. and Corning, New York, U.S.A.
Nalgene filter units were obtained from Nalge Co., Division of Sybron 
Corporation, Rochester, New York, U.S.A.
MiIlex Filtration Units were obtained from Millipore, London.
Disposable plastic ware was obtained from Sterilin, Teddington, England.
Plate glass strips for glass knives were obtained from LKB Productia, 
Sweden.
Moulds for constructing araldite blocks from TAAB Laboratories,
Reading, Berkshire.
Electron microscopy grids (3,0 mm copper, HF34, 200 mesh) were 
obtained from Graticules Ltd., Tonbridge, England.
Cells were routinely examined using a Leitz diavert microscope.
Electron microscopy was carried out on a Phillips 301 electron microscope,
6.1.10 LIVESTOCK
Nude or a thymic mice were kindly supplied by the a-nimal house of the 
Dermatology Department, Glasgow University. These animals were bred 
from MF 10 LA albino mice and supplied from the Mordan Institute for 
Animal Diseases, Edinburgh. Athymic mice were maintained in an isolator 
under sterile conditions throughout the period of experiments.
6.1.11 HUMAN TISSUE
Breast tumour tissue was kindly supplied by Health Board Hospitals, 
principally Stobhill General Hospital, Western Infirmary, Gartnavel 
General Hospital, Hairmyres Hospital, East Kilbride and Ballochmyle 
Hospital, Mauchline, Ayrshire.
Normal breast tissue was kindly supplied by Canniesburn Hospital, 
Bearsden, Glasgow,
6.1.12 ANTIBODIES
The monoclonal antibody (LE65) was kindly supplied by Dr. E.B. Lane 
(Lane, 1982).
Fluorescein conjugated rabbit anti mouse IgG was obtained from the 
Scottish Antibody Production Unit, Law Hospital, Carluke, Scotland.
6.2 TISSUE CULTURE SOLUTIONS
6.2.1 COMPOSITION OF MEDIA
(i) Basic media (FIO)
Ham's flO (lOx) 45 ml
deionised, distilled water 350 ml
non-essential amino acids (lOOx) 5 ml
HEPES buffer (IM) 9 ml
Sodium bicarbonate (7.5%) 2.5 ml
Sodium hydroxide (IN) added to 
pH 7.2
Media is then ’’tested" for 3 - 4  days at 37°c to ensure sterility.
(ii) Standard working media (FlO/10)
for maintenance and growth of established cell lines.
The following were added to the Basic Medium: - 
Foetal calf serum 50 mis (10%)
Glutamine 2raM
Penicillin 50 units/ml
(iv) Dissection BSS
Hanks balanced salt solution (BSS) 400 ml
penicillin (1 0 , 0 0 0 units/ml) 20 ml
kanamycin (1 , 000 ug/ml) 8 ml
streptomycin (10,0 0 0 yg/ml) 4 ^ 1
amphotericin g(fungizone) 3.5 ml
(iii) Primary working media (FlO/20)
for maintenance and growth of primary cultures.
The following were added to the Basic medium:-
Foetal calf serum 100 ml (20%)
Glutamine 2 mM
Penicillin 50 units/ml
Insulin 5jug/ml
iv) Digestion media (FlO/20/PSK)
The following were added to the primary working medium 
Kanamycin 10 jug/ml
Streptomycin 100 pg/ml
v) Collection medium (FIO/PSFK)
The following were added to the Basic medium;. 
Penicillin 250 units/ml
Streptomycin 250 jig/ml
Kanamycin
or
Gentamicin
Amphotericin /g fungizone
100 pg/ml
50 pg/ml 
2.5 pg/ml
vi ) Phosphate buffered BDTA 
Na Cl 
K Cl
Na PO^
^ 2  ^ 4  
EDTA
8g 
0.2g 
1.15g 
0, 2g 
0.2g
added to 1 litre of distilled water and pH raised to 7.2
(vii) Formal Saline
100 ml of 40% (w/v) formaldehyde plus 900ml 0.08M NaCI,
0.2M Na^SO^.
6.2.2 ANTIBODIES
Penicillin, Kanamycin and streptomycin were all prepared at the 
desired concentration in Hanks BBS.
Mitomycin C was made up in Standard working medium to the required 
concentration.
Gentamicin and Amphotericin ^  were obtained in sterile solution.
6.2.3 ENZYMES
(i) Collagenase - made up in Hanks BSS at a concentration of 2000 
units/ml.
(ii) Trypsin - 2.5% solution diluted 1 : 10 in the following diluent 
before use :-
Sodium chloride 6.Og
Trisodium citrate 2.96g
Tricine 1.79g
Phenol red O.OOSg
distilled deionised water 700 ml
pH of the diluent was adjusted to 7,8 and distilled water added 
until the osmolarity was equal to 290m osmol before addition to 
trypsin.
(iii) Protease neutral Dispase II - 2% solution made up in Hanks BSS.
6.2.4 HORMONES
Insulin was made up in Hanks BSS to 200 jug/ml and the pH raised to 8 
to facilitate solubilisation.
Steroid hormones were dissolved and stored in ethanol at -20^c.
When required the ethanol was blown off and the hormone redissolved 
in FI0/20 at the following concentrations, diluted with FlO/20 as 
required and stored at 4°c. 
stock concentrations
oestradiol 17 10 M
cortisol 10
To ensure that oestradiol and cortisol were completely soluble at 
these concentrations, stock solutions of tritiated hormones were 
made up and diluted in primary working medium. The level of radio­
activity in each dilution was counted and found to be identical to
the level obtained when hormones were aliquoted directly in small
volumes of ethyl alcohol. Therefore steroid hormones are completely 
soluble in FlO/20 at these concentrations.
Cholera toxin and Epidermal Growth Factor (EGF) were stored, lyophilized, 
at 4°c. When required they were dissolved in FlO/20 as stock solution 
(10 times required concentration) and stored at 4^c. The bulk of 
reconstituted EGF was stored at -20^c,
Prolactin was dissolved in FI0/20 containing phenol 3mg/ral and glucose 
50 mg/ml at a concentration of 100 jug/ral. Equal volumes of prolactin 
vehicle were added to control flasks.
sterilization of solutions in Sections 6,2,2 - 6.2,4 was carried out 
using either Nalgene or MiIlex filtration units, depending on the 
volume involved,
6,3 TISSUE CULTURE METHODS
6.3.1 PREPARATION OF PRIMARY CELL CULTURES FROM SOLID TISSUES
6.3.1.1 TISSUE COLLECTION
Tissue whether normal or neoplastic was collected fresh from the 
operating theatre and transported to the laboratory in a sterile 
container kept on ice. A portion of the tumour was retained for 
routine pathology, a second for oestrogen receptor determination and 
the remainder transferred asceptically to collection medium and stored 
at 4^c. Although viable cells could be recovered after storage 
overnight, a much greater yield was obtained when tumour cells were 
cultured within 4 hours of the removal of the biopsies.
6 .3.1.2 TISSUE DISSECTION
The tissue was transferred to a 9 cm. diameter petri dish containing 
25ml of dissection BSS. Any obvious pieces of fatty, fibrous or 
necrotic material were removed at this stage. The remaining tissue 
was then transferred to a fresh petri dish containing dissection BSS 
as before. The tissue was carefully chopped into pieces of about 
2mm cubed, using apposed scalpel blades. Care was necessary at this 
point not to damage the tissue by the use of excessive pressure and, 
for this reason, the scalpel blades had to be kept sharp (i.e, fresh 
scalpel blades used after approximately 30 cuts) and the chopping
completed as quickly as possible. The pieces were then transferred
by inverted pipette to a sterile universal container. The pieces were
allowed to settle by gravity. Any remaining fatty tissue, which
floated on top of the supernatant, was removed at this stage. The
supernatant was removed to a second sterile universal. Fresh dissection
BSS was added to the pieces, and again removed to a universal after
settling out of the material had occurred. This washing procedure
was repeated three times with dissection BSS and the pieces finally
resuspended in a medium containing high antibiotic concentrations
(F10/20/PSK). The suspension was transferred using an inverted
2
pipette, to a 25cm culture flask, collagenase added to a final 
concentration of 200 units/ml, and hormones or growth factors were 
added as required. The flasks were then incubated at 37°c for 3 - 7  
days until disaggregation of tissue was apparent by the formation of 
small clumps of cells and free cells on shaking the flask. The timing 
of this incubation varied with different types of tumour probably 
reflecting the level of collagen in the tumour.
After incubation the free cells and clumps of cells were spun out of
collagenase by transferring the suspension to a sterile universal
container and centrifuging at 200g for 5 minutes in an MSE bench
centrifuge. The pellet was then resuspended in FlO/20 medium and
2
transferred to 1) fresh 25cm culture flasks containing a feeder layer 
or collagen gel (see Section 6.3.3) or 2) a glass coverslip, coated 
with a monolayer of FHI, in a 24-well plate. The flasks were maintained 
in a hot room at 37°c and the coverslips in multiwell plates, were 
maintained in an incubator with 5% CO^ to allow growth of the cells. 
Medium and hormones were renewed regularly as indicated to be necessary
by a change in colour of the phenol red indicator. The cells were 
routinely inspected, before transfer or feeding, using an inverted 
microscope. The methodology is summarised in figure 6.1.
6.3.1.3 "LASFARGUE SPILLAGE METHOD"
Cells released by 'spillage* (Lasfargue & Ozzello, 1958) on slicing 
the tumour, were recovered from the original dissection BSS and 
subsequent washes by centrifuging at 200g for 5 minutes. The pellet 
containing 'spilled' cells and a large amount of cellular debris, was 
washed once with dissection BSS and resuspended in FlO/20, The cells 
were examined using an inverted microscope and then treated as cells 
released by collagenase digestion.
6.3.1.4 PLEURAL EFFUSIONS AND ASCITES FLUID
Fluid was collected from the patient in a buffered antibiotic solution 
(penicillin/streptomycin) and the solution cooled on ice prior to 
transport to the laboratory. Cells were recovered by centrifugation 
at 200g, washed 3 times in dissection BSS and resuspended in F10/20/PSK,
They were then plated onto a 25cra^  flask and grown at 37°c as described 
by Soule et (1973) and Cailleau ej^  (1974), Cells attached to
the substrate slowly over 2 weeks, with some clumps of cells growing 
in suspension during this period. Prior to feeding the cells, those 
in solution were centrifuged at 200g for 5 minutes and resuspended 
in fresh FlO/20.
Figure 6.1 - Procedure for the Dissociation o f  Breast Tissue into Cells
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6.3.2 SUBCULTURE OF CELLS 
6.3.2.1. TRYPSINISATIGN
Trypsin treatment was used to remove cells from attachment to the 
flask prior to counting or passaging into fresh flasks. The medium 
was removed from the cells to be trypsinised, and they were washed 
with phosphate-buffered EDTA. Trypsin solution was then added to 
cover the layer of cells and removed after 30 seconds exposure.
The flask was placed at 37°c and the behaviour of the cells noted.
When the cells were released from the surface of the flask, fresh 
medium was added to resuspend the cells and stop the action of trypsin.
The suspension could then be counted and innoculated into different 
flasks as desired.
6.3.2.2 DISPASE TREATMENT
Dispase was used as a more gentle method» of subculture than trypsinisation, 
where it was desired to separate one cell type from another. Medium 
was removed from the cells to be treated. Dispase solution was added 
diluted 1:9 with primary working medium (0.2% final concentration. The flask 
of cells was then incubated at 37°c until the desired cell type was 
observed detaching from the surface. The medium was then removed 
and the cells sedimented by centrifugation at 200g for 5 minutes 
followed by washing twice in medium to avoid any subsequent contamination 
by residual dispase. The selected cells could then be resuspended 
in primary working medium and used as required.
6.3,3 p r e p a r a t i o n OF CELLS FOR USE AS FEEDER LAYER MATERIAL
6.3.3.1 HUMAN FOETAL INTESTINE
An undifferentiated epithelial cell line (FHI-4) was produced from 
foetal intestine by the "evertion method", A long piece of foetal 
intestine was cut into pieces of approximately 5 cm. in length.
Using fine forceps, the pieces were everted. The pieces were 
then tied off at each end using sutures, and digested in either a 
concentrated collagenase solution (2,000 units/ml) at 37°c for 30 
minutes or a more dilute solution of collagenase (1,000 units/ml) at 
37^c for 2 hours. The dilute solution of collagenase usually gave 
the best results. At the end of the digestion period the suspension 
was centrifuged at 200g for 5 minutes and the resuspended material set 
up in 25 cm^ culture flasks which were incubated at 37^c. This 
method was used to set up lines of FHI which were frozen and stored 
in liquid nitrogen at -70^c. Cells were brought up from nitrogen 
as required.
A fibroblast cell line (FHI-F) was produced from foetal intestine by 
the "flushing method", A long piece of intestine was cut into smaller 
pieces . (7-8 cm) for ease of handling. These were flushed out with 
phosphate buffered EDTA using a large syringe. One end of each 
piece was then sealed off using a suture and the middle of the intestine 
filled with a 0.25% (v/v) trypsin solution. The other end was then 
also sealed and the piece of intestine left at 37°c for 30 minutes of 
trypsin digestion. After incubation, the end of the piece was opened 
and the trypsin or collagenase digest collected. This was then 
centrifuged at 200g for 5 minutes and the resulting pellet of cells
resuspended in FlO/20/PSK. The suspension was innoculated into 
25 cm^ culture flasks and incubated at 37°c. FHI-F cells were 
frozen and stored in liquid nitrogen until required.
6.3.3.2 INHIBITION OF CELL DIVISION OF FIBROBLAST CELLS
In order to use 3T3 or FHI-F cells as a feeder layer, division was 
prevented when cells reached a confluent monolayer. This was achieved 
by the action of mitomycin C, a safer and cheaper technique than X-ray 
irradiation (MacPherson & Bryden, 1971). The medium was removed 
from a monolayer of fibroblast cells and fresh FlO/10 medium added. 
Mitomycin C was added to a final concentration of 10 pg/ml and 
incubated for 2 hours at 37^c. The cells were then washed with medium 
and incubated for 2 hours at 37°c. The feeder layer of FHI-F or 3T3 
was then suitable for use. The monolayer of fibroblasts was stable 
and did not' divide for up to 2 weeks at which time the cells began 
to slough off into the medium.
6.3.3.3 VITROGEN 100 COLLAGEN COATED DISH PREPARATION
A thin layer of vitrogen 100 collagen was placed inside the dish to 
be coated. The vitrogen was evaporated to dryness with a stream of 
sterile air and then rinsed with sterile phosphate buffered saline.
The coated surface was then washed twice with FI0/20 medium to hydrate 
the collagen.
6.3.4 CELL COUNTING
The flask of cells to be counted was trypsinised, as described in
Section 6.3.2,1. The cells were suspended in an arbitrary volume 
of medium and 20ml counting fluid added to 0.4ml cell suspension.
This was then counted on a Coulter Counter at settings of threshold 
and current apperture suitable for the cell type being studied.
6.3.5 CELL FIXING
6.3.5.1 CELL FIXING USING METHANOL
Medium was removed from cells to be fixed and Hanks balanced salt
solution (BSS) was then added to cover the cells and remove any
remaining medium. This was poured off, and a (1:1 v/v) mixture of 
BSS and methanol was added to the culture. After this was discarded, 
methanol alone was added to cover the cells, and exposure maintained 
for 10 minutes. Then the cells were washed once with fresh methanol 
and dried. This method of fixation was suitable for photography 
since it reduced the thickness of cell layers,
6.3.5.2 CELL FIXING USING FORMAL SALINE
Medium was removed from cells to be fixed, and they were washed twice
with Hanks BSS. The cells were washed once with formal saline, and
then fixed in fresh formal saline for 30 minutes at 20°c and air dried 
at room temperature.
6.3.6 CELL STAINING
Gierasa stain was added to cover cells and allowed to stand for 2 minutes 
This was then diluted with 10 volumes of water, allowed to stand for
a further 10 minutes and then discarded. The cells were then washed 
with distilled water until no more stain could be detected and the 
flasks left to dry.
6.3.7 ASSAY FOR THE EFFECT OF HORMONES OR GROWTH FACTORS 
ON COLONY GROWTH
6.3.7.1 DIRECT MEASUREMENT
Tumour cells, isolated after collagenase treatment, were transferred 
onto a monolayer of FHI cells. Medium and hormones were replaced 
every 2 days and after 4 - 6  weeks the cells were fixed and stained.
The colonies were then counted and the total colony area in a flask
determined using a dissection microscope and this was expressed 
relative to a control flask.
6.3.7.2 AUTORADIOGRAPHIC MEASUREMENT
Tumour cells isolated after collagenase treatment were transferred 
onto a monolayer of FHI cells grown on glass coverslips. Medium
and hormones were replaced every 2 days and, after 2 - 4  weeks of
culture, medium was replaced for a final time and cells were grown
q
in the presence of lOjuCi/ml ( H) thymidine for three hours. The 
medium was removed and the cells fixed with formal saline (as described 
in 6.3.5,2). The coverslips were removed, placed in racks and the 
acid soluble nucleotides removed by washing twice with 5% (v/v) TCA 
at O^c for 5 minutes, and twice with water at O^c for 4 minutes.
The coverslips were finally rinsed in ethanol and dried. Coverslips 
were mounted (cells uppermost) with Depex mounting fluid onto microscope 
slides and processed for autoradiography.
Preparation of Microscope Slides for Autoradiography 
Microscope slides were dipped in gelatin/chrome alum and dried at 
room temperature. They were then covered with ARIO fine grain 
autoradiographic stripping film, dried under a stream of cold air 
and placed in a light tight box. Autoradiographs were stored at 
room temperature in the dark. The period of exposure varied depending 
on the extent of radioactive incorporation.
After the exposure period, slides were developed with D19 developer 
at 20^c for 5 minutes, washed in water for 2 minutes and fixed for 
5 minutes, with a 1 : 5 dilution (v/v) of Amfix. After washing for 
4 minutes with water, slides were stained using freshly diluted 
Giemsa (1 : 20 in water) for 1 minute. The stained washed 
autoradiographs were air dried and second coverslips mounted on top 
with Depex. The number of cells growing in a colony and the extent
3
of ( H) thymidine incorporation could be measured by grain counting.
The changes in these parameters, as a result of hormone treatment, 
were then calculated.
6.3.8 PHOTOGRAPHY
After fixing and staining cells were photographed on a Leitz diavert 
microscope using a Leitz camera attachment and using Panatomic X film.
6.3.9 ELECTRON MICROSCOPY OF CELLS
Cells in culture were prepared for electron microscopy by the method 
described by Kuhn (1981), Briefly this involved fixing the cells
for 30 minutes at 4°c with 2% (v/v) glutaraldehyde in Sorensons* 
phosphate buffer (pH 7.4). Cells were washed twice with phosphate 
buffer at 4^c. The cells were stained with 2% osmium tetroxide for
30 minutes at 4^c, and washed twice with phosphate buffer. The 
cells were dehydrated for 30 minutes in 75% ethyl alcohol, and 10 
minutes each in 3 washes of absolute alcohol. The monolayer was 
then scored with a scalpel and covered with propylene oxide. When 
suitable areas of cells floated from the substrate they were picked 
up and transferred to araldite with fine forceps. The araldite 
blocks were cured for 24 hours at 60^c. Thick sections were cut 
down the araldite block and mounted, stained and viewed by light 
microscopy. When the desired cell type was reached,thin sections 
were cut. Sections were cut with glass knives using an LKB ultratome 
(Wbdel 4B01A with control unit 4802A). Ribbons of thin sections 
were floated off the glass knives and picked up on copper grids.
Grids were then stained with uranyl acetate and lead citrate as 
described by Mercer & Birbeck, (1966). The grids were then air 
dried at room temperature and sections viewed in a Phillips 301 
electron microscope.
6.3.10 STEROID HORMONES IN FOETAL CALF SERUM
The concentration of steroid hormones in foetal calf serum was 
determined by radioimmunoassay which was kindly performed by Dr. G. 
Beastall (Glasgow Royal Infirmary).
6.3.11 CARCINOEMBRYONIC ANTIGEN ASSAY
The concentration of carcinoembryonic antigen (CEA) was measured by 
enzyme linked immunoassay using a kit purchased from Abbot Diagnostics. 
This assay was kindly performed by Mrs. M. Meiklejohn,
6.3.12 FLUORESCENT LABELLING OF TONOFILAMENTS
Coverslips were fixed for 20 seconds in acetone to remove all 
membranes, and then mounted, cells upward, on a slide. The coverslips 
were then covered with a dilution of stock solution of the monoclonal 
antibody LE65 (the monoclonal antibody was produced from mice immunized 
with a crude preparation of tonofilaments from Ptk^ cells. Lane (1982)). 
This was incubated at 37°c for 30 minutes in a humid atmosphere. The 
coverslip was then washed twice with phosphate buffered saline for 
15 minutes at room temperature. The coverslips were then covered 
with a film of fluoresoein - conjugated rabbit anti-mouse IgG. A 
second coverslip was mounted on top of the coverslip on the slide.
The coverslips were then examined with a Leitz photomicroscope using 
U.V. illumination, and filters to reduce background fluorescence.
7. RESULTS
7.1 BREAST STROMAL CELLS
All attempts to grow breast epithelial cells after standard collagenase 
treatment, in absence of a feeder layer, resulted in overgrowth by 
fibroblasts. The fibroblasts grew rapidly, coating the flask in 
less than one week and no epithelial growth was ever noted.
If the tumour pieces were maintained in collagenase for 2 weeks and 
then the collagenase concentration was slowly reduced, some epithelial 
growth resulted, but the epithelial cells were quickly overgrown 
once the fibroblasts had adapted and begun to attach to the substrate.
Feeder layers, in particular Foetal Human Intestine (FHI-4) were 
able to retard but not completely prevent, fibroblast growth 
(Fig. 7.1, 7.14). In some cases epithelial colonies, after 2-3 
months growth with no visible fibroblastic growth, would become 
overgrown with fibroblasts in the space of one week. The trigger 
for this rapid increase in fibroblast growth was not evident, though 
in several cases passaging a primary culture onto a fresh feeder 
layer apparently stimulated stromal growth. This overgrowth does 
not occur in all tumours. However, fibroblast cells could be easily 
grown from any grade or class of breast tumour. Five fibroblast 
cell lines were established (B-ECOF, B-MCPF, B-LIMF, B-GORF and B-JECF) 
and could be cultured indefinitely in FlO/10 medium. The cells grew
and divided rapidly and were not contact inhibited. This resulted
in cells piling up in layers, several cells thick. The spindle
Figure 7.1 - Fibroblast Colony
A fibroblast colony growing on FHI-4 feeder layer from a 
tumour B-123. Cells had been in culture for 3 months 
before fibroblast growth began. Cells were fixed with 
ethanol and stained with Giemsa as described in Section
6.3,5 to 6.3.6 (Magnification X 120).
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Figure 7.2 - Breast Fibroblast Cells
Cells from the breast fibroblast cell line B-MCPF,
This demonstrates the alignment of the spindle shaped 
fibroblast cells which results in the characteristic whirls 
Cells were fixed with ethanol and stained with Giemsa 
as described in Section 6.3.5 to 6.3.6 (Magnification X 360
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Figure 7,3 - Breast Fibroblast Cells
Cells from the breast fibroblast cell line B-MCPF. This 
illustrates the alignment of the spindle shaped cells in 
a layer several cells thick. Cells were fixed with 
ethanol and stained with Giemsa as described in Section 
6,3.5. to 6.3.6, (Magnification X 960),
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shaped fibroblast cells grow aligned in the same direction and form 
characteristic whirls (Fig. 7.2 and 7,3),
A standard oestrogen receptor assay was performed on the five 
fibroblast cell lines, grown in the presence and absence of oestrogen 
(10 ^M) and cortisol (10 ^M). All five were found to be receptor 
negative in both the cytosol and nuclear fraction.
7.2 FOETAL HUMAN INTESTINE (FHI-4)
The most successful way of preventing overgrowth of epithelial cells 
by fibroblasts has been to coat the surface of the flask. This 
prevents the attachment of the fibroblasts to the substrate and so 
inhibits their growth. The plating efficiency and growth of breast 
epithelial cells on three different feeder layers and on collagen 
coated flasks were determined (Table 7.1). While growth of breast 
epithelial colonies was achieved on all the surfaces, the most 
successful method was a feeder layer of human epithelial cells (FHI-4) 
derived from foetal intestine. However growth, albeit at a lower 
level, was routinely achieved using either of the mitomycin C treated 
fibroblast cell lines. Therefore these fibroblast feeder layers 
could be used as an alternative if problems arose in using FHI-4, 
because of similarities between this cell line and breast epithelial 
cells. Although growth of colonies was achieved on collagen coated 
flasks sporadically, only a very low number of small colonies grew. 
Collagen coating the substrate was also the least effective method 
of preventing fibroblasts attaching and growing.
Figure 7.4 - Foetal Human Intestine Cells (FHI-4)
A monolayer of Foetal Human Intestine (FHI-4) after growth 
in culture for 4 months without passaging. The cells 
were fixed with ethanol and stained with Giemsa as 
described in Section 6.3.5. to 6,3.6. (Magnification X 960)
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Table 7.1 The Effect of the Substrate on Growth of Cultured
Breast Tumour Cell
After digestion of tumour pieces with collagenase 
was completed, single and clumps of epithelial cells 
were recovered by centrifuging at 200g for 5 minutes 
The pellet of cells was washed once with, and 
resuspended in, fresh medium and the cells grown 
on the support indicated for 3 weeks at 37°c.
The cells were then fixed and stained with Giemsa. 
The number and size of the epithelial colonies 
was counted using a dissecting microscope 
(at 40 X magnification). Results are expressed as 
mean + the standard deviation.
Substrate Number of Experiments
Number of 
Colonies
Area 
(mm 2 )
Vitrogen 100 6 5.2 +2.9 4.0 t  2.4
collagen
3T3 7 19.4 ± 11.5 15.0 ± 9,9
(Mitomycin C treated)
FHI-F 12 17.1 ± 9.4 27.6 ± 20.5
(Mitomycin C treated)
FHI-4 22 75.9 ± 26.9 184.8 t  98.9
(Epithelial cell-line)
The cell line, FHI-4, is an undifferentiated epithelial cell line 
established from human foetal intestine by collagenase treatment.
The cells are contact inhibited such that they grow to a confluent 
monolayer and then stop dividing. The cells remain as a monolayer, 
with no piling up, for several months (Fig. 7,4), This strong 
contact inhibition means that treatment with mitomycin C is unnecessary.
Attempts to plate FHI-4 cells onto a monolayer of the same cells 
resulted in no change in the monolayer. This means that breast 
epithelial cells on a feeder layer of FHI-4 can be passaged onto 
a fresh feeder layer with no interference from the original feeder 
layer.
However FHI-4 have a relatively slow growth rate compared with 
either of the fibroblast cell lines. The cell density must be 
maintained fairly high on passaging (cells can only be split up 
to 1:4) otherwise the cells stop dividing. The FHI-4 have a finite 
life in culture such that after 20-25 passages (-— -1 yr ) the cells 
stop growing. But these disadvantages are outweighed by the 
superior growth of the breast epithelial cells on this type of 
feeder layer.
The FHI cells were assayed for oestrogen receptors and found to be 
receptor negative in both cytosol and nuclear fractions.
The epithelial origin of the cells was demonstrated using electron 
microscopy. Fig. 7.5 shows that FHI-4 cells grow as a monolayer. To the 
right of the figure there is a small amount of surface activity with
Figure 7.5 - Electron Micrograph of FHI-4 Monolayer
A monolayer of foetal human intestine cells (FHI-4) was 
prepared and sectioned for electron microscopy as described 
in Section 6.3.9. Thin sections were cut at right angles 
to the plastic substrate (Magnification X 16,870),
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Figure 7.6 - Electron Micrograph of FHI-4 Monolayer
A monolayer of foetal human intestine cells (FHI-4) was 
prepared and sectioned for electron microscopy as described 
in Section 6.3.9. Thin sections were cut at right angles 
to the plastic substrate (Magnification X 81,000).
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a line of tonofilaments just below the cell membrane. The cell is 
relatively inactive in terms of secretory products as shown by the 
high nuclear to cytoplasmic ratio, the small amount of golgi 
apparatus (to left of nucleus) and a low number of inactive 
mitochondria distributed throughout the cell. The interdigitation 
between cells and a tight junction are illustrated in Fig. 7.6.
A small number of glycogen granules can be seen in the cytoplasm 
of both cells.
7.3 CULTURE OF NORMAL BREAST CELLS
Cells were cultured from 3 mamraoplastic reductions after slicing 
and digestion with collagenase. Growth on a normal plastic substrate 
resulted in only fibroblast growth in all three cases. There was 
no evidence of any epithelial growth on a feeder layer of FHI-4 cells.
7.4 BREAST TUMOUR CELLS FROM PLEURAL EFFUSIONS AND
ASCITES FLUID
Attempts were made to culture cells from one pleural effusion (B-PES) 
and one ascites fluid (AF-ES). Cells from both tumours grew in 
solution and stuck down slowly over a period of 2 weeks. The cells 
then grew in culture for 4 months in FlO/20 medium with a steadily 
decreasing growth rate. The cells grew both on a feeder layer of 
FHI-4 cells (Fig. 7,7 and 7.8) and on a normal plastic substrate
(Fig. 7.9). The different morphology appears to be a result of
the differences in substrate since cells could be transferred from 
plastic onto a feeder layer with the resultant change in morphology. 
The cells of the pleural effusion (Fig. 7.8) appear to be pushing
Figure 7.7 - Cultured Cells from a Pleural Effusion
Two epithelial colonies from the pleural effusion B-PES, 
grown on a feeder layer of FHI-4 cells, are shown.
Cells were prepared as described in Section 6,3,1.4. 
Cells were grown in culture for 10 days then fixed with 
ethanol and stained with Giemsa as described in Section
6.3.5. to 6.3.6, (Magnification X 120).
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Figure 7.8 - Cultured Cells from a pleural Effusion
An epithelial colony from the pleural effusion B-PES, 
grown on a feeder layer of FHI-4 cells. Cells were 
prepared as described in Section 6.3.1.4. The cells 
were grown in culture for 10 days, fixed with ethanol 
and stained with Giemsa. Note the increase in density 
of feeder layer at the edge of the epithelial colony 
(Magnification X 300),
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Figure 7.9 - Cultured Cells from a Pleural Effusion
Cells from the pleural effusion B-PES on a plastic 
substrate. Cells were prepared as described in Section 
6.3.1.4. After growth in culture for 2 weeks cells 
were fixed with ethanol and stained with Giemsa. A 
number of the cells shown appear to be multinucleated. 
Ihis property was not shown by cells grown on a feeder 
layer (Magnification X 300).
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back the feeder layer, as shown by the increase in density of the 
cells round the colony.
During four months in culture there was no evidence of stromal growth. 
The original cells from both the pleural effusion and the ascites 
fluid were oestrogen receptor negative. In culture neither B-PES 
nor AF-ES showed an increase in growth after treatment with oestradiol 
(10 ^M) and cortisol (10 ^M).
7.5 CULTURE OF BREAST TUMOUR CELLS
Attempts to culture cells from breast tumour biopsies were most 
successful when, after digestion of tumour pieces in collagenase, 
the suspension of breast cells was transferred onto a feeder layer 
of FHI-4 cells. They settled down onto the feeder layer and grew 
slowly over a period of weeks as individual colonies (Fig. 7.10).
These colonies grew from small clumps of tissue (2-10 cells 'probably 
epithelial since they were resistant to collagenase) and had a 
distinctive ring at the edge of the colony.
In total, 65 from 76 biopsies gave rise to ring colonies (85%) while 
the remainder gave rise to only fibroblasts. The ring colonies 
could be derived from 1) both primary and secondary tumours, 2) tumours 
of all histological grades and 3) both oestrogen receptor positive 
and negative tumours.
Figures 7.11 - 7,13 show a typical ring colony derived from an oestrogen 
receptor positive tumour, B-MGR. In the centre of the colony there
Figure 7.10 - Flasks of Cultured Breast Cells
2
25 cm flas)^s of FHI-4 with ring colonies of breast 
tumour cells (staining more heavily). Cells were 
prepared as described in Section 6.3.1.2, Cells were 
grown for 4 weelcs, fixed with ethanol and stained with 
Giemsa. The flask on the right was treated with
-9 . -7
oestradiol (10 M) and cortisol (10 M) and this caused 
an increase in the number of ring colonies.
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Figure 7.11 - Cultured Breast Tumour Cells
A ring colony (B-MGR) growing on a feeder layer of 
FHI-4. Cells were prepared as described in Section
6.3.1.2. from an oestrogen receptor positive tumour. 
The cells were grown in culture for 4 weeks then fixed 
with ethanol and stained with Giemsa aà described in 
Section 6.3.5, to 6.3.6. (Magnification X 120).
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Figure 7.12 - Cultured Breast Tumour Cells
A ring colony (B-MGR) growing on a feeder layer of FHI-4. 
Cells were prepared as described in Section 6.3.1.2. from 
an oestrogen receptor positive tumour. The cells were 
grown in culture for 4 weeks then fixed with ethanol and 
stained with Giemsa as described in Section 6.3.5. to 6.3, 
(Magnification X 300). The heavily stained area in the 
centre of the colony is probably the tissue from which 
the colony grew.
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is a small heavily stained area which is probably the piece of 
tissue from which the colony grew. In this case the ring structure 
appears outwith the colony, on the feeder layer cells, as if the 
breast cells are causing the death of the feeder layer cells. At 
higher magnification, this colony is unusual because there are cells 
with two dif ferent types of morphology within the same colony 
(Fig. 7.13). The cells at the top edge of the colony are spindle 
shaped and almost fibroblast like in morphology. It is possible 
that this colony may contain a mixed population of epithelial and 
fibroblast cells though the slow growth rate makes a fibroblast 
origin of these cells unlikely.
The second colony (Fig. 7.14 - 7.16) was derived from another 
oestrogen receptor positive tumour (B-MHE). In Fig. 7.14 there 
is a small fibroblast colony above the top edge of the colony and 
its growth has been inhibited by the feeder layer, in this colony 
the ring structure appears within the colony and may be due to 
alignment of cells at the colony edge (Fig. 7,15). At certain 
points the colony can be seen growing over the feeder layer with 
apparently no ill effects to the feeder layer. At the highest 
magnification (960 X) in Fig. 7.16 the morphology of the ring colony 
cells (staining darker) can be compared with FHI-4 cells, to the top 
of the figure. The large spherical nuclei and prominant nucleolus 
shown by both cell types, are characteristic of epithelial cells.
Fig. 7,17 demonstrates further that some ring colonies can grow on 
top of the feeder layer with no ill effects to the FHI cells. This 
shows a tear in a ring colony derived from an oestrogen receptor 
negative tumour (B-EMA) with the feeder layer cells visible below.
Figure 7.13 - Cultured Breast Tumour Cells
The edge of a ring colony (B-MGR) growing on a feeder 
layer of FHI-4. This illustrates the differences in 
morphology, occasionally seen, between cells within a 
colony. Cells were prepared as described in Section
6,3.1.2. The cells were grown in culture for 4 weeks
and then fixed with ethanol and stained with Giemsa 
as described in Section 6.3.5. to 6.3.6. (Magnification 
X 300).
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Figure 7.14 - Cultured Breast Tumour Cells
A ring colony (B-MHE) growing on a feeder layer o f FHI-4, 
The heavily stained area at the top edge of the colony 
is a small fibroblast colony. Cells were prepared as 
described in Section 6.3.1.2. from an oestrogen receptor 
positive tumour. The cells were grown in culture for 
4 weeks then fixed with ethanol and stained with Giemsa 
as described in Section 6.3.5, to 6.3.6. (Magnification 
X 120).
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Figure 7.15 - Cultured Breast Tumour Cells
The edge of a ring colony (B-MHE) growing on a feeder 
layer of FHI-4. This illustrates the 'ring* structure 
at the edge of the colony. Cells were prepared as 
described in Section 6.3.1.2. The cells were grown in 
culture for 4 weeks then fixed with ethanol and stained 
with Giemsa as described in Section 6.3.5. to 6.3.6. 
(Magnification X 300).
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Figure 7.16 - Cultured Breast Tumour Cells
This shows the edge of a ring colony (B-MHE) on a feeder 
layer of FHI-4 (lighter staining cells). The cells 
were prepared as described in Section 6.3.1.2. from an 
oestrogen receptor positive tumour. Cells were grown 
in culture for 4 weeks then fixed with ethanol and 
stained with Giemsa as described in Section 6,3.5. to
6,3.6. (Magnification X 960),
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Figure 7.17 - Cultured Breast Tumour Cells
A gap in cells of a ring colony (B-EMA) showing the 
feeder layer cells (FHI-4) below. Cells were prepared 
as described in Section 6.3.1.2. from an oestrogen 
receptor negative tumour. cells were grown in culture 
for 4 weeks, then fixed with ethanol and stained with 
Giemsa as described in Section 6.3.5. to 6.3.6, 
(Magnification X 960).
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7.6 SUBCULTURING BREAST TUMOUR CELLS
Trypsin digestion, although a harsher method, was eventually selected 
as the routine method of subculturing. Use of dispase was discontinued 
because the ring colonies and feeder layer usually detached 
simultaneously as a sheet of cells. This sheet of cells then had 
to be disrupted mechanically which was probably very damaging to 
the cells and resulted in small clumps of cells. The removal of 
dispase by centrifuging and washing is time consuming. In both 
cases only a small percentage of the cells grew after passaging.
In approximately half of the samples, subculturing was found to cause 
a rapid increase in fibroblast growth. For this reason the effect 
of hormones and growth factors was determined on primary cultures 
and not passaged cells,
7.7 BREAST TUMOUR CELLS BY "LASFARGUE" METHOD
Breast tumour cells released on the slicing of the biopsy were 
recovered by centrifuging and washing. While a large number of 
cells could be recovered (in some cases >10^ cells/ml) a large 
proportion (>85%) appeared damaged when viewed by phase contrast 
microscopy and tested for exclusion of Trypan Blue. However, if 
these cells were placed in culture, approximately 30% (5 biopsies from 
16) gave rise to epithelial colonies. In all cases there was a very 
low contamination with stroma though in most cases this grew to a
significant level within 2 weeks. Figs, 7,18 and 7.19 show a typical
colony prepared by the Lasfargue spillage technique from an oestrogen 
receptor positive tumour, B-PST-L. In Fig. 7,18 several individual 
fibroblast cells can be seen round the colony.
Figure 7.18 - Cultured Breast Tumour Cells
Breast tumour cells from an oestrogen receptor positive 
tumour (B-PST-L) on normal substrate. Cells were 
prepared by the Lasfargue * spillage* method as described 
in Section 6.3,1.3. Cells were grown in culture for 
10 days then fixed in ethanol and stained with Giemsa 
as described in Section 6.3,5, to 6.3.6. (Magnification 
X 300).
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Figure 7.19 - Cultured Breast Tumour Cells
Breast tumour cells cultured from an oestrogen receptor 
positive tumour (B-PST-L) on normal substrate. Cells 
were prepared by the Lasfargue * spillage* method as 
described in Section 6,3.1“, 3. Cells were grown in 
culture for 10 days then fixed in ethanol and stained 
with Giemsa as described in Section 6.3.5, to 6,3.6.
(Magnification X 960).
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When the 'spillage cells' were transferred onto a feeder layer of 
FHI-4 then colonies were established in approximately 70% of 
attempts (8 from 11 biopsies). These colonies were identical in 
morphology to those formed after collagenase treatment. In the 
small number of experiments performed the response of the 'spillage* 
cells to hormonal stimulation was identical to that observed in 
colonies derived by collagenase treatment.
7.8 CHARACTERISATION OF CELLS IN RING COLONIES
In order to demonstrate that the ring colonies are human breast 
cancer cells they must be shown to be both epithelial and malignant.
7,8.A Evidence of the Epithelial Nature
1. The morphology of the cells under light microscopy is consistent 
with them being epithelial. The cells form the characteristic 
paving-like arrangement seen in culture and have large spherical 
nuclei and prominent nucleoli (Fig. 7.16). However in some 
cases the morphology differs from that of a classical epithelial 
cell such as in Fig, 7.13 where the cells are more spindle 
shaped and fibroblast like.
2. The electron micrographs, shown in Figs, 7,20 - 7.22, further 
demonstrate the epithelial nature of these cells. Fig. 7,20 
shows that this ring colony is several cells thick. These cells 
are involved in active synthesis as demonstrated by 1) low nuclear 
to cytoplasmic volume, 2) large amounts of rough endoplasmic 
reticulum (RER) which is swollen, probably with secretory
products, 3) large amounts of glycogen granules, 4) a number 
of active mitochondria some of which are very large, and 5) the 
large number of ribosomes. The epithelial nature of the cells 
is shown by 1) the surface activity (evident between cells),
2) tonofilaments, 3) tight junctions (thickening of cell 
membrane at areas of cell contact) which may be desmosomes, 
and 4) the prominent nucleolus in the lower cell.
The contrast between a healthy and damaged cell within a ring colony 
is shown in Fig. 7.21. The lower cell contains extensive golgi 
apparatus and large amounts of mitochondria and RER. However, the 
upper cells show extensive vacolation and 4-5 degenerating mitochondria. 
Anoxia, is known to cause similar symptoms in the cell ultrastructure.
Fig. 7.22 shows a cell with a large amount of tonofilaments and tight 
junctions (possibly desmosomes) with tonofilaments going into them.
The upper ceil again shows a large number of organelles.
The fact that all figures show that the ring colony is several layers 
thick implies that the sections have been cut close to a piece of 
tissue released by the collagenase digestion, since the ring colonies 
appear to consist largely of a monolayer when studied by light 
microscopy,
3. The ring colonies were screened for the presence of tonofilaments 
using a monoclonal antibody (LE65) raised against a small molecular 
weight component of tonofilaments (Lane, 1982), The cells were 
fixed with acetone to remove all membranes and labelled with
Figure 7.20 - Electron Micrograph of Cultured Breast Tumour Cells
Cells from an oestrogen receptor positive tumour (B-TMC) 
were cultured on a monolayer of FHI-4 cells. The cells 
were prepared and sectioned for electron microscopy as 
described in Section 6.3.9. Thin sections were cut at 
right angles to the plastic substrate as described in 
Section 6.3.5. to 6.3.6. (Magnification X 22,050).
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Figure 7.21 - Electron Micrograph of Cultured Breast Tumour Cells
Cells from an oestrogen receptor positive tumour (B-TMC) 
were cultured on a monolayer of FHI-4 cells. The cells 
were prepared and sectioned as described in Section 6.3.9, 
Thin sections were cut at right angles to the plastic 
substrate (Magnification X 22,050).
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Figure 7.22 - Electron Micrograph of Cultured Breast Tumour Cells
Cells from an oestrogen receptor positive tumour (B-TMC) 
were cultured on a monolayer of FHI-4 cells. The cells 
were prepared and sectioned as described in Section 6,3.9. 
Thin sections were cut at right angles to the plastic 
substrate (Magnification X 49,500).
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Figure 7.23 - Cultured Breast Tumour Cells
A ring colony from the breast tumour, B-MLI.
The cells were prepared as described in Section 6.3.1,2. 
The cells were fixed with acetone and photographed under 
phase contrast microscopy as described in Section 
6.3.12. (Magnification X 540).
Figure 7.24 - Immunofluorescence of Breast Tumour Cells
A ring colony from the breast tumour, B-MLI.
The cells were prepared as described in Section 6,3.1,2. 
The cells were fixed with acetone and labelled with 
monoclonal antibody LE65 (against a component of 
tonofilaments) as described in Section 6.3,12.
Cells were photographed using ultra violet illumination 
(Magnification X 540),
- 1 4 0  -
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the monoclonal antibody. Antibody binding was visualised using 
a fluorescein conjugated rabbit anti mouse igG. Figs. 7.23 and 
7.24 demonstrate that the fluorescence is localised over the 
ring colony. All ring colonies from three tumour cell lines 
tested (B-SUS, B-MLI and B-BOO) reacted with the monoclonal 
antibody. The low molecular weight component of tonofilaments 
is thought not to be expressed in established cell lines which 
explains why the FHI cells of the feeder layer failed to react 
with the monoclonal antibody.
7.8.B Evidence of Malignant Nature
Originally it was planned to demonstrate the malignancy of these cells 
by showing the presence of plasminogen activator, but the feeder 
layer of FHI-4 cells or 3T3 cells both produce plasminogen activator 
in large quantities (I. Freshney, personal communication) and so this 
method was discounted.
Nude or athymic mice were used in an effort to show that tumours could 
be raised after injection of the cultured cells. Six samples of 
cells were taken from 3 tumours, 1 pleural effusion (B-PES) and 2 
breast tumour biopsies (B-ALO and B-PAC), after the cells had been 
in culture for 3 weeks. The cells from the pleural effusion were
5
injected in 0.5 ml. medium containing 5 x 10 cells. The cells 
from the ring colonies were injected with a feeder layer of FHI-4 
cells so that the exact number of tumour cells is unknown. ■ The 
mice were then maintained under asceptic conditions for 6 months 
with no evidence of tumour growth. The animals were then sacrificed
Table 7.2 Measurement of Carcinoembryonic Antigen (CEA)
Carcinoembryonic Antigen levels were measured using
an enzyme-linked immunoassay kit produced by Abbot
Diagnostics. The assay was kindly performed by
Mrs. Marion Meiklejohn on a suspension of cells in
2
spent medium from a 25cm flask. Range of the 
assay 0 - 6 0  ng/ml. Results are expressed as mean 
+ the standard deviation.
-  -
Concentration (ng/inl)Cells
4/9FHI
4/7TMC on FHI
4/9MLI on FHI
4/9SUS on FHI
and no evidence of any cancerous growth was found at post mortem 
inspection. However, the failure to produce tumours does not 
indicate that the cells are not malignant since there is normally 
only a low rate of success in causing a tumour and the rate of
success is lowest with breast tumours.
Table 7.2 shows the levels of carcinoembryonic (CEA.) antigen in 
spent medium from three cultures of breast tumour and a feeder layer 
control. Only one tumour, B-SUS, produced CEA. The concentration 
is just greater than the range, detected by this assay in serum 
samples from normal specimens, (98% of which are below 5ng/ml).
However, since this concentration was achieved by a very low number 
of cells it demonstrates that at least a portion of the cells in 
ring colonies are, by this definition, malignant. This result also 
implies that the tumour cells are fully viable after 3 weeks in
culture since they are able to produce a high level of tumour marker.
7.9 HORMONAL MODULATION OF COLONY GROWTH
The level of several steroid hormones was measured by radioimmunoassay 
in the batch of foetal calf serum used inthe following experiments. 
Table 7.3 shows that oestradiol is the only steroid hormone present 
in detectable amounts and that it can be reduced by 60% by charcoal 
stripping. The oestradiol concentration in the medium is 37pM (or 
15pM after stripping) compared with 10 ^M (lOOOpM) used to stimulate 
growth of the ring colonies. It was, thus, decided not to use 
charcoal stripped serum since a) the change in oestradiol concentration 
was minimal with respect to the level being used to stimulate and
b) charcoal stripping may remove proteins or factors required for 
the ring colonies to grow (such factors have been demonstrated 
(Munir & Leake, 1982) for human endometrial cells in culture).
2
Growth was measured in 25cm flasks by boih counting individual 
colonies and measuring the areas they covered. The cell density 
was measured in both control and hormone treated flasks and was found to 
be identical and therefore an increase in colony area should reflect 
an increase in cell number. Treatment of a control feeder layer 
flask with hormones or growth factors had no effect on the FHI-4 cells 
and which always remains as a monolayer.
Unfortunately the size of the breast tumour biopsies meant that only 
one or two measurements oould be performed on each tumour. it was 
therefore not possible to construct a dose response curve and so 
the physiological concentration of the hormone and the concentrations 
of growth factors previously reported to cause a stimulation in 
growth of breast cells were used.
Table 7.4 shows the effect of a number of hormones and growth factors
on the growth of ring colonies. Cortisol (10"^M) but not oestradiol 
-9(10 M) caused an increase in growth of the breast tumour cells.
-9 -7However, oestrogen (10 M) and cortisol (10 M) seem able to act
synergistically to cause a marked stimulation of colony growth.
Cholera toxin (O.lng/ml) on average also caused an increase in growth 
although the effects were variable between tumours.
Prolactin (ljug/ml) appeared to cause an increase in the colony number 
(possibly reflecting an increase in plating efficiency) but had no
Table 7.3 Steroid Hormone Levels in Foetal Calf Serum
The concentration of steroid hormones in the batch 
of foetal calf serum used in all experiments was 
measured by radioimmunoassay. This assay was kindly 
performed by Dr. G. Beastall (Royal Infirmary, Glasgow)
Hormone Foetal Calf Sernm
Charcoal Stripped 
Foetal Calf Serum
Cortisol (nM) <  28 <  28
Testosterone (nM) < 0.7 < 0,7
Oestradiol (pM) 185 77
Progesterone (nM) < 2.0 <  2.0
Table 7.4 Hormonal Modulation of Colony Growth
This table shows the effect of various hormones and 
growth factors on the growth of treated epithelial ring 
colonies. Results are expressed as a percentage 
increase with respect to the control flask (probability 
that control and hormone treated populations are the 
same as calculated by a paired *t» test. N.S. = no 
significant difference, i.e. P>0.1). Cells were 
prepared as described in Section 6.3,1.2 and growth 
measured as described in Section 6.3.7.1.
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effect on the total number of cells. On average, there was no 
effect of epidermal growth factor (EGF) (Ing/ml) treatment. When 
EGF was added with oestrogen and cortisol it appeared to prevent the 
stimulation caused by the steroids.
Table 7.5 illustrates that biopsies from older postmenopausal patients 
grew better in culture than cells from menopausal or premenopausal 
patients. This suggests that well differentiated tumours are more 
successful in culture than poorly differentiated tumours, since 
younger patients tend to have a more aggresive and hence pathologically 
poorly differentiated disease.
This suggestion is reinforced by Table 7.6 which demonstrates that 
oestrogen receptor positive tumours (well differentiated) are,on 
average,more successful in culture than tumours without receptor or 
with abnormal receptor. This implied that different classes of 
tumour, according to receptor status, might respond differently to 
hormonal stimulation. Table 7.7 shows the response to hormone 
treatment related to the oestrogen receptor status of the original 
tumour. Oestradiol receptor positive tumours show more of a response 
to oestradiol while cortisol exhibits a greater stimulation of 
receptor negative tumours. Both classes of tumour are stimulated 
by oestradiol plus cortisol. However the response of the receptor 
negative tumours is greater. Receptor negative tumours also show a 
greater tendency to respond to stimulation by EGF.
In order to demonstrate that the feeder layer was not responsible for 
effects of hormones, ring colonies were stimulated with oestradiol and 
cortisol. Table 7.8 shows that the response of the ring colonies
Table 7.5 Effect of Menopausal Status on Colony Growth
This table shows the effect of menopausal status on the 
growth of epithelial ring colonies in the absence of 
added growth factors. Menopause was defined as 
occurring between 48 and 52 years of age (unless a 
patient's form reported otherwise). Cells were 
prepared as described in Section 6.3.1.2. and growth 
measured as described in Section 6.3.7.1. Results are 
expressed as the mean (+ the standard deviation) of each 
individual experiment conducted. The standard deviations 
are large because of differences in the size of biopsies 
and, hence, the number of cells seeded into a flask.
However growth of cells from postmenopausal samples is 
significantly different from that of both premenopausal 
(colony number P<0,05 and area P<0,005) and perimenopausé 
(colony number P <0.05 and area P < 0.005) samples as 
calculated by a paired 't * test.
Status Age No. of Samples
Average Growth
No. of Colonies
2
Area {mm )
Premenopausal 48 8 23.7 27.1
{ t  35.9) (+ 34.3)
Perimenopausal 48-52 7 28.2 30.8
(1 18.6) (Î 23.1)
Pos tmenopaus al 52 36 44.8 99.9
(Î 45.6) (Î 82.3)
Oestrogen Receptor 
Status
No. of 
Samples
■ Average Growth
No. of Colonies
2
Area (mm )
Receptor Positive 
(+/+)
25 47.9
(+ 33.0)
105.6
(Î 80.9)
Receptor Negative 
(o/o)
21 26. 8
(± 23.1)
55.3
{ t  48.8)
Abnormal Receptor 
(o/+ , +/o)
6 29.8
i t  17.3)
53.0
(± 40.0)
Table 7.7 Effect of Hormones on the Growth of Colonies with Respect
to the Oestrogen Receptor Status of the Original Tumour
This table shows the effect of hormones on the growth 
of ring colonies in relation to receptor status of the 
original tumour biopsy, from which the cells were derived. 
Oestrogen receptor positive tumours contained more than 
10 fmol/mg protein in the cytosol and more than 
1000 fmol/mg DNA in the nucleus. Cells were prepared 
as described in Section 6.3.1.2, and growth measured as 
described in Section 6.3,7,1. Individual results 
represent the mean of all experiments conducted (probabilil 
that the effect of hormones on the growth of cells from 
receptor positive tumours is the same as the effect on 
cells from receptor negative tumours as calculated by a 
paired *t* test. N.S. = no significant difference, t
i.e. P>0.1).
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Table 7.8 Effect of Oestradiol Plus Cortisol on the Growth of
Ring Colonies on Different Substrates
This table illustrates the effect of different feeder
layers on the stimulation in colony growth caused by
- 9 -7oestradiol (10 M) and cortisol (10 M). Cells were
prepared as described in Section 6.3.1,2. and growth 
measured as described in Section 6.3,7,1. Results 
are expressed as the mean (± the standard deviation) 
of each individual experiment conducted.
Substrate Number of Experiments
% Increase in 
Colony Number
% Increase in 
Area
FHI-4 
(Primary passage 
o f  tumour cells)
14 46.3 (±21.5) 74.8 (±24.6)
FHI-4 
(Second passage 
of tumour cells)
8 68.8 (+37.8) 117.6 (±42.2)
FHI-F 
(Mitomycin C 
treated)
8 44.1 (±16.4 54.8 (±16.6)
3T3
(Mitomycin C 
treated)
7 43.3 (±18.4) 63.8 (±16.4)
to the steroids occurred at a constant level irrespective of the 
type of feeder layer. The fact that passaged tumour cells are more 
responsive to stimulation suggests that the more responsive cells 
are being selected as time in culture increases.
7.10 AUTORADIOGRAPHY OF RING COLONIES
Autoradiographs of hormone treated (figs. 7.27 - 7,29) and untreated 
(figs. 7.25 and 7.26) ring colonies show that there are both more 
cells and a higher proportion of more heavily labelled cells in 
hormone treated ring colonies. There appears to be some secondary 
structure in the arrangements of labelling since it also appears to 
form rings (of labelled nuclei) within the colony. Control coverslips 
showed that there was no labelling of the feeder layer irrespective 
of the hormone treatment. A small number of widely dispersed 
fibroblasts showed some labelling but these were easily recognisable 
by the spindle shape of the nucleus. The autoradiographs demonstrated 
that there is a mixed population of ring colonies (at least three 
types - unlabelled, partially labelled and totally labelled) as 
illustrated in fig. 7.29.
Table 7,9 shows that the number of cells labelled or the average number 
of grains over the nuclei (or radioactive incorporation) can be used 
to measure hormone stimulation. As it was not possible to measure 
TCA soluble counts the increase in grains could be due to an increased 
uptake of labelled precursor.
The use of autoradiographs would mean that more parameters could be 
studied and this would allow construction of a dose response curve
for drugs or mitogens for each biopsy because stimulation or inhibition
can be detected in small amounts of tissue. This is demonstrated
in Table 7.10 where the effect of three hormones was determined on
cells from one small biopsy vhich would normally have allowed only 
2
one 25cm flask to be seeded. The stimulation achieved is in 
agreement with the results obtained in Table 7,4,
Figure 7.25 - Autoradiograph of Cultured Breast Tumour Cells
Autoradiograph (Magnification X 300) of an untreated ring
3
colony after incubation with ( H) thymidine as described i 
Section 6.3,7,2. Cells were derived from a biopsy 
of breast cancer (B-BOO) as described in Section
6,3.1.2, and had been in culture for 3 weeks.
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Figure 7.27 - Autoradiograph of Cultured Breast Tumour Cells
Autoradiograph (Magnification X 300) of a hormone treated 
(oestradiol and cortisol)ring colony, after incubation with
3
( H) thymidine as described in Section 6. 3.7. 2. Cells were 
derived from a biopsy of breast cancer (B-BOO) as 
described in Section 6.3.1.2, and had been in culture 
for 3 weeks.
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Figure 7.28 - Autoradiograph of Cultured Breast Tumour Cells
Autoradiograph (Magnification X 960) of a hormone treate 
(oestradiol and cortisol) ring colony after incubation
3
with ( H) thymidine as desçribed in Section 6.3.7.2, 
Cells were derived from a biopsy of breast cancer 
(B-BOO) as described in Section 6.3.1.2. and had been 
in culture for 3 weeks.
— 15 ~l —
Figure 7,29. - Autoradiograph of Cultured Breast Tumour Cells
Autoradiograph (Magnification X 120) of hormone treated
(oestradiol and cortisol) ring colonies after incubation 
3with ( H) thymidine as described in Section 6.3.7.2.
Cells were derived from a biopsy of breast cancer 
(B-BOO) as described in Section 6.3.1.2. and had been 
in culture for 3 weeks.
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Table 7.9 Measurement of Hormonal Stimulation in Autoradiographs
The number of ring colonies and the area covered by 
ring colonies were counted as described in Section 6.3.7.1 
The number of labelled cells per coverslip was counted 
on a Leitz inverted microscope. The number of grains 
per nuclei was counted in twenty nuclei per coverslip 
on a Leitz inverted microscope under oil immersion. All 
measurements were performed on ring colonies derived from 
the breast tumour B-BOO prepared as described in Section
6.3.1.2. Results are expressed as mean - the standard 
deviation.
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Table 7.10 Effect of Hormones on f H) Thymidine Incorporation Into
the Nuclei of Ring Colony Cells
Autoradiographic measurements were performed on ring 
colonies derived from the breast tumour, B-MLI.
The number of grains per nuclei was counted in twenty 
cells per coverslip and averaged for 3 coverslips. 
Autoradiographs were prepared as described in Section
6.3.7.2. Grains were counted on a Leitz inverted
microscope under oil immersion. Results are expressed 
as mean - the standard deviation.
Addition Concentration Grains/Nuclei % Increase over control
Control - 63.2 f  17.7 -
Cholera 0.1 ng/ml 70.0 t  2 5 . 0 + 10,8
toxin
EGF 1 ng/ml 62.7 + 18.2 - 1.0
Oestradiol -910 M 86.8 t 23.5 + 37.2
8. DISCUSSION
8.1 STROMAL GROWTH
The rapid growth of fibroblast cells from breast tissue has been 
widely reported (Lasfargue & Ozzello, 1958; Owens e_t 1976 ). This 
is one of the major reasons for the failure of most early attempts to 
culture breast epithelial cells (Orr & McSwain 1955; Lasfargue & 
Ozzello 1958; Whitescarver 1974). Despite the failure to detect 
steroid hormone induced stimulation of growth, a number of other 
groups have reported the presence of steroid hormone receptors in 
fibroblasts both iu vitro (Fleming ek ^,1980; Ozasa et al,1980;
Eil & Marx,1981) and in vivo (Pertschuk e_t al, 1980). As yet there 
have been no reports of cultured breast fibroblasts containing steroid 
hormone receptors. This may be due to receptors being lost as the 
cells adapt to, or are selected for, rapid growth in culture. It is 
worthwhile continuing to search for a breast fibroblast cell line 
which responds to steroid hormone stimulation since the ease and 
speed with which these cells grow would make them an attractive system 
in which to study the mechanism of steroid hormone action. In 
particular, Skarda (1983) has recently suggested that stroma 
secrete EGF in response to oestrogen stimulation which in turn induces 
growth of breast epithelial cells. Hence stroma may play an important 
part in the effects of oestrogens on breast tissue.
8.2 FEEDER LAYER
The main purpose of a feeder layer is to prevent stromal attachment 
(Rheinwald & Green 1975 a;b). All four feeder layers tested were
successful at inhibiting but not completely preventing stromal growth. 
The least effective method tested was coating the flask with collagen. 
It may be that the coating used was too thin since Yang et ad (1981) 
have reported that the thickness of the collagen layer is important 
in regulating which cells types can attach and grow on the surface.
The source of the collagen may also be critical, since a higher rate 
of success has been reported using collagen prepared from rat tail 
(Yang al, 1981; Furmanski e^ al, 1981). The second possible role 
for the feeder layer is that cells in the monolayer (even mitomycin C 
treated) are able to condition the medium by releasing factor(s) vhich 
aid the plating and growth of malignant epithelial cells. There was 
little difference between the growth of breast cells on a feeder layer 
of mitomycin C treated, 3T3 or FHI-F fibroblast cells. Namba ejt ad 
(1981) and Smith e;t ^  (1981a) also found that the type of fibroblast 
line used as a feeder layer did not have an effect on cell growth.
This means that either fibroblasts do not condition the medium or that 
this property is common to all fibroblast cell lines, and that no 
specificity is exhibited.
However, the greatly increa.sed plating efficiency and growth, achieved 
when using the epithelial cell line, FHI-4, as a feeder layer suggests 
that some of the factors which are able to stimulate breast tumour 
cells are released only by specific cell types. This capacity of 
some cell types to condition medium was first proposed by Armstrong 
& Roseneau (1978). The idea has been extended by some groups 
(Stampfer et al,1980; Smith et ad,1981a) which now use "spent" or 
conditioned medium from certain cell types to stimulate growth of 
both normal and malignant cells in culture. These growth stimulating 
factors appear to be specific, since the cell lines used to provide
the conditioned medium are all human and epithelial. The specificity 
of the growth factors secreted by the FHI-4 cells would explain why 
these cells were found to provide the most effective feeder layer 
since, like breast tumour cells, FHI-4 cells are undifferentiated 
human epithelial cells. Therefore it may be possible to improve the 
growth of breast tumour cells on collagen layers by adding conditioned 
medium from FHI-4 cells.
During growth of the cells from the pleural effusion BP-ES, the cells 
exhibited differences in morphology when grown on a plastic substrate 
(Fig. 7.9) or a feeder layer of FHI-4 (Fig.7.8). Similarly, a
substrate dependent change in morphology has been reported for growth 
of MCF-7 cells on plastic or collagen (Leung & Shiu, 1982). Ihis 
change in morphology was accompanied by a change in growth rates in 
response to serum or hormonal stimulation. However Table 7.10 shows 
that, despite growth on different feeder layers, the breast cells 
continued to respond to approximately the same relative degree to 
hormonal stimuli.
8.3 BREAST TUMOUR RING COLONIES
The success rate of 80% in establishing ring colonies from breast 
tumour biopsies is higher than previously reported. Green (1982) 
reported that only 30-40% of human tumours (depending on the site of 
origin) gave rise to significant colony growth. The difference may 
be due to the fact that Green reported the success rate in cloning 
tumour cells, and it is possible that clumps of tumour cells (as 
prepared by collagenase treatment) grow better than single cells. A 
second possible reason for the differences may be that the feeder layer
of FHI-4 cells, is particularly suited for culturing human breast 
tumour cells.
Both the mechanical (Lasfargue 'spillage* technique) and enzymatic 
(collagenase digestion) methods of preparing cells from breast tumour 
biopsies gave rise to similar cell growth. The cells exhibited a 
similar morphology under the light microscope and a similar response 
to stimulation by hormones on growth factors (Section?.7). The only 
difference was the ability of the cells prepared by the Lasfargue 
method to grow on a plastic substrate without rapid overgrowth by 
stromal cells. This suggests, in agreement with the original report 
(Lasfargue & Ozzello, 1958), that the cells prepared by the Lasfargue 
'spillage* technique contain a very low proportion of stromal cells.
The yield of viable cells is higher using the enzymatic method, with 
a large percentage (> 75%) of the cells, prepared by the mechanical 
method, damaged or lysed. Hamburger ^  ^  (1982) have reached similar 
conclusions, that the enzymatic and mechanical methods of preparing 
cells from tumours produced the same type of cells and that the yield 
of viable cells was much higher when using an enzymatic method.
A number of groups have reported either no success at all or, at least, 
difficulties in passaging primary cultures of breast tumours (Kirkland 
et al, 1979; Stempfer ei^  ^,1979; Yang et ^,1981). Trypsin treatment, 
used to passage breast tumour cell ring colonies growing on an FHI-4 
feeder layer, appears to have an average success rate (-~'70%). This 
rate is higher than reported by Kirkland ejt al^  (1979) and Stampfer e^
(1979) but less successful than that for cells grown on collagen gels 
prepared from rats tails (Yang et al 1981).
8.4 CHARACTERISATION OF. BREAST RING COLONIES
8.4.1 EPITHEL lAL NATURE
Several groups have relied heavily on the morphology, under light 
microscopy, of cells cultured from breast biopsies to prove that the 
cells were epithelial (Gaffney & Pigott, 1978; K1evjer-Anderson & 
Buehring,1978; Yang et al,1981; Poulson e^ al,1982). Some groups 
have then assumed that the epithelial growth is all, or at least 
partly, due to malignant cell growth (Klevjer-Anderson & Buehring,1978; 
Poulson et a^ , 1982) and not to the normal epithelial cells that must 
remain from the original infiltrated tissue.
Most groups reported that epithelial cells within individual islands 
of either normal or malignant cultured cells generally do not overlap 
each other and that growth is restricted to a monolayer (Buehring & 
Williams, 1976 ; Kirkland et aT,1979). They therefore conclude that
growth patten (e.g. monolayer versus multilayered growth) cannot be 
used to distinguish between normal and malignant cells. The growth 
of the cells as a ring colony can also occur with tumour or normal 
cells. Growth is not necessarily invasive and occurs largely as a 
monolayer on top of the feeder layer. There have been reports that 
some of the cells prepared from breast tumour biopsies exhibit 
outgrowths capable of penetrative growth into collagen gels (Yang ^  al,
1981) or feeder layer (Smith e^ ad,1981b). This may be related to 
the portion of ring colonies which appear to push aside or kill the 
feeder layer (Fig. 7.12). In the future it may be possible to relate 
these properties to the invasive potential of the tumour.
Electron microscopy is the most popular method to demonstrate the 
epithelial origin of primary cultures derived from solid breast 
biopsies (Stampfer ^  al, 1980; Smith e]k a^, 1981 a;b). However 
these studies have been limited to showing the presence of desmosomes, 
tonofilaments, microvilli, etc. in order to prove the cells to be 
epithelial. In this study (Figs. 7.20 - 7.22) all these 
characteristic features of epithelial cells were seen. In particular, 
active golgi bodies, rough endoplasmic reticulum, and mitochondria 
suggest that the cells are involved in active protein synthesis and 
secretion. This indicates that the majority of the cells remain 
healthy and viable after two weeks in culture.
There have been no studies which compared the morphology with that of 
the original tumour or studied the changes in morphology in the cells 
after hormonal stimulation or at different periods of time in culture. 
There have been a number of studies of the ultrastructure of 
established cell lines from pleural effusions (Russo et al, 1976; 1977; 
Osborne & Lippman, 1978) and solid tumours (Buehring & Hackett, 1974). 
Buehring & Hackett (197 4) found a great variation in the ultrastructure 
of cells in lines established from solid tumours. This ranged from 
cell lines which resembled cells in primary biopsies through to cells 
which contained either a variable amount of, or no, desmosomes and 
tonofilaments.
Ultrastruetur al studies of the cell line MCF-7 have shown that under 
certain conditions it closely resembles the original tumour from which 
the line was derived (Russo et 1976; 1977) and that changes occur
on hormonal stimulation (Vic eù 1982). Recently Stegner (1982)
has reported that ultrastructural differentiation (such as the presence 
of golgi vesicles, desmosomes, interdigitations, microvilli, cytoplasmic
inclusions) can be used to predict the receptor status of the tumour. 
This is further evidence that the degree of differentiation can be 
used to predict the presence-of oestrogen receptors and hence hormone 
dependence. The one sample studied was consistent with this report 
since the cells were derived from a receptor positive tumour and were 
found to be well differentiated.
The use of immunofluorescence to label to nofilaments in the ring colonies 
while providing further evidence that the cells are epithelial also 
conforms with the predictions of Lane (1982). This report predicts 
that antigen is only present in epithelial cells which have been in 
culture for a short period (i.e. the ring colonies) and not in long 
term cultured cells (i.e. FHI-4). This technique is potentially very 
useful since in the future it could be used to demonstrate the 
localization, over ring colonies, of a number of other human, breast 
or tumour markers such as the milk proteins lactalbumin or casein.
Sasaki ^  (1981) have raised antibodies against a number of surface 
proteins on breast cells. The antibodies have been used to study the 
origins of a number of primary and established breast cell cultures.
This technique could be adopted to study the binding of plant lectins 
to the breast ring colonies. The extent of binding to cultured breast 
cells of the lectin Concanavalin A (Furmanski et al,1981) has been 
related to the prognosis of the patient and early recurrence of disease, 
While the binding of the peanut agglutin to the carbohydrate moiety 
of milk fat protein on the surface of breast epithelial cells has been 
proposed as a marker of the presence of the oestrogen receptor (Klein,
1982), The binding, and extent of binding, of these antibodies and 
lectins to ring colonies could be used to highlight differences in
morphology between colonies, and hence cell types, derived from the 
same tumour. This would, hopefully, confirm that the cells within 
the ring colony are typical of the parent tumour, rather than highly 
selected,
8.4.2 MALIGNANT ORIGIN OF CELLS
There is a great deal of variation in reports of the rate of success
in establishing tumours in nude mice. However, it is generally
accepted that breast tumours are least likely to give rise to tumours
in nude mice (Shimosata ejk aT, 1976; Freshney, personal communication;
*
Taylor-Papadimitrou, personal communication). The reasons for the 
low success may be related to the difficulties in establishing cultures. 
Giovanella ot (1974) reported a higher rate of success using cultured 
cells from established cell lines, Hgwever, the number of cells 
injected was very important. It is therefore probably not surprising 
that the three attempts to generate tumours from primary cultured cells 
did not succeed. it is generally accepted that failure to generate 
a tumour in nude mice does not prove that the cells are not malignant. 
Different cell numbers in the innoculate and cells from different 
passage numbers should be tested.
The secretion of carcinoembryonic antigen (CEA) by one of the primary 
cell lines indicates that at least some of the cells cultured in ring 
colonies are malignant. Not all breast tumours secrete CEA, Walker
(1980) reported that 50% (45/90) of primary breast cancers produced 
CEA, resulting in significant serum levels. The percentage appears 
to be lower in established cell lines with only 1 out of 26 secreting 
CEA (Lippman ejt 1976).
Plasminogen activator has been proposed as a marker of malignancy but 
it is produced by both normal and malignant breast cells in culture 
(Kirkland ejt 1979; Yang ^  al, 1980b) and by feeder layers of 
FHI and 3T3 cells (Freshney, personal communication). Therefore 
any attempt to use plasminogen activator as a marker would require 
determination of the molecular weight. This would be justified if 
reports that secretion of plasminogen activator is related to invasive 
potential or hormone dependence are substantiated (Sherman et al,1980; 
Thorsen^1982).
In the future it may be possible to use immunofluorescence to localize 
tumour markers on ring colonies to determine if all the ring colonies 
are derived from malignant cells.
8.5 STIMULATION OF RING COLONY GROWTH
8.5.1 HORMONAL STIMULATION
A number of systems used as models of breast cancer, such as MCF-7 
cells (Osborne al, 1976; Butler el^  al, 1982) and DMBA - induced 
tumours in rats (Cohen & Hilf, 1974) have been shown to be very 
sensitive to insulin. It was not possible to grow ring colony cells 
in the absence of insulin (Laing, 1980).
The glucocorticoid receptor has been detected in a large proportion 
of human breast tumours with estimates varying from 33% (Teulings & 
Gilse, 1977) to 50% (Osborne & Lippman, 1978). Some caution is required 
in interpretation of this data, in that most of the supporting stroma 
(fibroblasts, leukocytes and adipocytes) are glucocorticoid target
tissues and contain glucocorticoid receptors. Osborne & Lippman (1978) 
also found that 3 out of 4 established cell lines from pleural 
effusions contained glucocorticoid receptors but responded to 
glucocorticoid treatment with a decrease in both growth and DNA 
synthesis. However, glucocorticoids have been widely reported as 
stimulating the growth of primary cultures from both normal and 
malignant breast cells (Gaffney & Pigott, 1978; Stampfer et al, 1980;
Yang et al, 1981),
Cortisol was found to stimulate the growth of cells in the ring 
colonies in agreement with these earlier reports. However, there 
have been no reports of the extent of response to cortisol vitro 
being related to the original tumour, in terms of, say, receptor status. 
However, Klevjer - Anderson & Buehring (1980) did report that 
hydrocortisone stimulated growth of malignant cells more frequently 
than growth of normal cells.
Reports of the response of primary cultured breast cells to oestrogen 
treatment have varied from no response (Kirkland e;t sQ, 1979) to a 
variable stimulation (Klevjer - Anderon & Buehring, 1980; Stampfer 
et al, 1980). Part of the explanation may lie in the fact that the 
response to oestradiol was more distinct when tumours were divided 
with respect to the receptor status of the original tumour tissue. 
However, the response to oestrogen treatment, both in ring colonies 
(Table 7.4) and in published reports of primary cultures of breast cells, 
is much lower than that originally reported for MCF-7 cells (i.e. a 
doubling in the number of cells in 8 days relative to a control), 
although MCF-7 cell lines no longer respond to oestrogen stimulation 
to this extent (Page et ad,. 1982).
There have been reports of hormones or growth factors acting 
synergistically in the stimulation of breast cells. There have been 
no previous reports of oestrogen and cortisol acting synergistically 
to cause an increase (74.8%) in cell number. It is unlikely that 
this is caused by oestradiol inducing glucocorticoid receptor since 
this stimulation was greater (125%) in cells derived from oestrogen 
receptor negative tumours than in similar cells from receptor positive 
tumours (39.6%). Similarly there have been no reports of cortisol 
causing induction of the oestrogen receptor.
The effects of prolactin on cultured breast tumour cells are controversial 
There have been no receptors for, or response to, prolactin detected in 
cell-lines derived from pleural effusions (Osborne & Lippman, 1978), 
but DMBA - induced breast tumours in rats are very sensitive to 
prolactin (Asselin & Labrie, 1978), Prolactin is also known to play 
an important part in growth and development of rodent mammary glands 
(Turkington, 1972 ). Klevjer - Anderson & Buehring (1980) found that 
prolactin stimulated the growth of normal cells more frequently than 
malignant cells. Treatment of the ring colonies caused an increase 
in the number of colonies but no corresponding increase in the number 
of cells. This suggests that prolactin increases the plating efficiency 
but not the rate of growth.
8.5.2 STIMULATION BY GROWTH FACTORS
Cholera toxin and other factors which increase intracellular cAMP have 
been widely reported as stimulating the growth of primary cultures of 
both normal and malignant breast cells (Taylor - Papadimitriou et al,
1980; Yang et al,1980; Yang et al, 1981; Stampfer, 1982). There
have been reports of a more variable response to cholera toxin in 
malignant breast cells, the response in the ring colonies was also 
found to be variable. This may be due to the already elevated levels 
of cAMP in some breast tumours (Elliot ^  al, 1981).
Epidermal growth factor (EGF) has been reported as stimulating normal 
breast cells in culture (Kirkland et al, 1979; Stampfer ^  al,1980;
Yang et al, 1980) but EGF treatment of cells derived from malignant 
tissue has been reported as causing occasional stimulation (Yang et al, 
1980) or no response (Kirkland e^ al, 1979). EGF treatment of cells 
in ring colonies, while variable, had on average no net effect. The 
failure of EGF to stimulate growth of the ring colonies could be 
explained if one of the factors secreted by the FHI-4 feeder layer 
was EGF. But when oestradiol, cortisol and EGF were administered 
simultaneously then there was no stimulation, suggesting that EGF could 
block the stimulation by oestradiol and cortisol and hence could not 
be one of the factors released by the feeder layer.
In the future it may be possible to use immunofluorescence to determine 
if hormones and growth factors can cause changes in protein induction 
and synthesis in cultured cells. It may also be used to detect 
different cell types by their differing responses to hormonal stimulation.
A number of groups (Kirkland ejt ^,1979; Klevjer - Anderson & Buehring , 
1980; Yang ejt a].,1981) have reported culturing epithelial cells with 
different types of morphology in primary cultures. The primary cultures 
giving rise to ring colonies also contain a mixed population of epithelial 
cells (possibly up to three types). This is best demonstrated by
autoradiography by the differing patterns of labelling (Fig, 7.29).
It is widely accepted that breast tumours dm vivo contain a mixture 
of different malignant epithelial cells.
8.6 POTENTIAL USES OF AN IN-VITRO SYSTEM
The fact that the growth pattern of primary cultures from breast 
biopsies can be related to the menopausal status or oestrogen receptor 
status of the original tumours (Tables 7.5 - 7,7) indicates that some 
of the properties of the primary tumours are retained in culture and 
reflected in the growth pattern. This suggests that cells cultured 
from the breast tumour biopsies could be typical of the original tumour 
and, therefore, used to predict such things as hormone responsiveness 
or drug sensitivity of the tumour within the patient. However,
Von Hoff has shown that the vitro - d^ vivo correlation remains 
60% for sensitivity and 90% for resistance over a wide range of tumour 
types from a number of laboratories (Green, 1982). These figures are 
comparable with the accuracy of oestrogen receptor determination on a 
fresh biopsy in predicting hormone dependence. Therefore, the 
correlation between response of the cultured breast cells and growth 
of the tumour in vivo would have to be shown to be an improvement over 
the oestrogen receptor values, currently used to predict hormone 
dependence, in order to Justify the extra cost involved in cell culture 
This correlation between cultured cells and the primary biopsy would 
most easily be tested by measuring the oestrogen receptor content of 
the ring colonies, (possibly by thaw - mount autoradiography (Stumpf 
et al 1981)) and comparing the receptor content with that of the 
original tumour.
The, close correlation between the two methods of measuring hormonal
3
stimulation means that ( H) thymidine incorporation can be confidently 
related to cell growth. The advantage of autoradiography is that an 
increased number of experiments could be performed on each biopsy 
(such as Table 7.10). This would allow the construction of dose 
response curves for a number of drugs and hormones, permitting the 
comparison of different drugs and drug concentrations. In general 
terms, the system could be used to study in detail the effects of 
different hormones and growth factors, under controlled conditions, 
to provide information on the factors which control growth of breast 
tumours. In clinical terms this system could be used to predict the 
aggressiveness of individual tumours and thereby to stratify patients 
for adjuvant therapy. Cell culture could also be used to select the 
most suitable type of drug therapy for each individual patient by 
studying the growth inhibition of cells cultured from the primary 
tumour.
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